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HOST-SPECIFIC PLASMACYTOID DENDRITIC CELL DEFENSES IN THE PRESENCE OF HUMAN AND MACAQUE SKIN CELLS INFECTED WITH B VIRUS
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ABSTRACT
Plasmacytoid dendritic cells (pDC) are a specialized group of circulating dendritic cells that respond to viral nucleic acids with Type I IFN production as well as other cytokine and chemokines. These
pDC responses lead to the production of antiviral molecules and recruitment of defense cells. During
zoonotic B virus infection, a simplex virus of the subfamily Alphaherpesviridae, our lab has observed that
infected individuals who succumb to infection have little-to-no-antibody or cell-mediated defenses. To
identify whether this was partly due to failure of pDCs to produce antiviral interferon responses or produce chemokine and cytokines, we tested the hypothesis that B virus modulates the IFN response during zoonotic infection by blocking pDC activation and subsequent IFN signaling pathways to circumvent host defenses, while these pathways remain intact in the macaque hosts. We showed that human
pDCs respond to B virus through the production of IFN-, IL-1, IL-6, TNF-, MIP-1/ and IP-10. Human pDCs co-cultured with B virus infected fibroblasts produced fewer cytokines and at lower levels.
The macaque response to B virus was measured using PBMCs, as there are no specific reagents available

to enrich macaque pDCs. Human and macaque PBMCs produced IFN- when exposed directly to B virus
infected lysates. Co-cultures of PBMCs with B virus infected fibroblasts from both hosts failed to produce any significant amounts of IFN-. To quantify the antiviral effects of PBMC induced IFN-, we
measured B virus titers after exposure to supernatants from B virus exposed PBMCs, PBMC co-cultures
with infected fibroblasts and exogenous recombinant Type I IFN. Our data further suggest that B virus
resistance was not due to virus specific blockade of the Type I IFN signaling pathway because STAT-1
was activated in infected fibroblasts when treated with Type I IFNs. These data demonstrate for the first
time that B virus replication is unimpeded in the presence of any source of IFN- in either host cell type.
In conclusion, this dissertation shows that the IFN- production by both hosts in response to B virus is
similar and that IFN- treatment of B virus infected fibroblasts did not reduce B virus replication.

INDEX WORDS: Plasmacytoid dendritic cells, Interferon, Fibroblasts, Macaque, Herpes B virus, Macacine
herpesvirus 1, STAT-1, Innate immunity

HOST-SPECIFIC PLASMACYTOID DENDRITIC CELL DEFENSES IN THE PRESENCE OF HUMAN AND MACAQUE SKIN CELLS INFECTED WITH B VIRUS

by

NICOLE BROCK

A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy
in the College of Arts and Sciences
Georgia State University
2014

Copyright by
Nicole Brock
2014

HOST-SPECIFIC PLASMACYTOID DENDRITIC CELL DEFENSES IN THE PRESENCE OF HUMAN AND MACAQUE SKIN CELLS INFECTED WITH B VIRUS

by

NICOLE BROCK

Committee Chair:

Committee:

Julia Hilliard

Richard Dix
Yuan Liu

Electronic Version Approved:

Office of Graduate Studies
College of Arts and Sciences
Georgia State University
May 2014

iv
DEDICATION
This dissertation is dedicated to the loves of my life; to Josh, without your unfailing support, love
and wisdom I would not have completed this journey. Thank you for always being there for me and for
your advice that was sometimes difficult to hear. Thank you for pushing me to excel no matter the odds
or circumstances. Also, thank you for making sacrifices so that I could pursue my dream.
This dissertation is also dedicated to my children; Shelby, you were created at the beginning of
this journey and have given me the desire to be a strong role model and someone you can look up to; to
Lilia for teaching me patience in overcoming tough challenges and showing me how to fall down and get
back up; and to Aengus, for teaching me to appreciate and embrace the unexpected.
I love you all beyond the edges of the universe. Thank you for being my motivation, my drive,
my heart, and my soul.

“When we love, we always strive to become better than we are. When we strive to become
better than we are, everything around us becomes better too.” Paulo Coelho

v
ACKNOWLEDGEMENTS
First, I’d like to acknowledge my mentor Dr. Julia Hilliard. Thank you for your mentorship, life
advice, patience and flexibility. I appreciate all that you have done for me.
Many thanks to my committee members, Drs. Richard Dix and Yuan Liu, for their helpful advice
and their guidance in helping me maneuver through my dissertation work and teaching me to become a
better scientist.
Thank you to Nikie Brooks, for her hard work and dedication to the lab and to my success.
Thank you to Marty Wildes for his artistic ability in drawing blood. Without his amazing skills
and consideration, my project would not have been possible.
Thank you to the professors who kindly allowed sharing of macaque tissues and to Kay Lee
Summerville and Carmen Nash and their staff with Yerkes Primate Center for making it all possible.
A special thanks to Dr. Mugdha Vasireddi for spending many laborious hours contemplating my
results, my next steps and for troubleshooting. Also, many thanks for your support, kind words and
friendship throughout my Ph.D.
Lastly, thanks to Drs. David Katz, Irina Patrusheva, and Peter Krug, and to Wei Shi for always
being available for advice and direction.
Thanks to the many other lab members in both the diagnostic and research labs for their personal support throughout the years.
Last, but most certainly not least, to LaTesha Warren, without your guidance and wisdom I
could not have completed this dissertation.

vi
TABLE OF CONTENTS
ACKNOWLEDGEMENTS .......................................................................................................... v
LIST OF TABLES ..................................................................................................................... ix
LIST OF FIGURES..................................................................................................................... x
LIST OF ABBREVIATIONS....................................................................................................... xii
1

INTRODUCTION................................................................................................................1
1.1

1.1.1

B virus ................................................................................................................1

1.1.2

Immune Response to herpes viruses .................................................................. 12

1.1.3

Type I Interferon Pathway ................................................................................. 28

1.2
2

Literature Review ......................................................................................................1

Research Goals ........................................................................................................ 31

MATERIALS AND METHODS ............................................................................................ 33
2.1

Cells and Viruses...................................................................................................... 33

2.2

Virus Stocks and Plaque Assay ................................................................................. 33

2.3

Rhesus Macaque Fibroblast Isolation and Maintenance ............................................ 34

2.4

B Virus Kinetics in Fibroblasts................................................................................... 35

2.5

Human and Macaque PBMC Isolation....................................................................... 36

2.6

Plasmacytoid Dendritic Cell Isolation........................................................................ 36

2.7

Western Blot Analysis .............................................................................................. 36

2.8

ELISA for Interferon- .............................................................................................. 37

2.9

PBMC Response to B Virus ....................................................................................... 38

vii

3

2.10

Luminex Assay ....................................................................................................... 38

2.11

B Virus Titer Reduction Assay ................................................................................. 39

2.12

Plasmacytoid Dendritic Cells Response to B virus .................................................... 39

2.13

B virus modulation of IFN signaling pathway .......................................................... 40

2.14

Plasmacytoid dendritic cells do not support B virus replication ............................... 41

2.15

Statistical Analysis ................................................................................................. 42

RESULTS AND DISCUSSION ............................................................................................. 43
3.1

Human plasmacytoid dendritic cell response to B virus ............................................. 43

3.2

HFFs in pDC co-cultures produce infectious B virus ................................................... 58

3.3

IFN- from pDCs is dependent on B virus dose ......................................................... 59

3.4

pDCs do not support productive B virus replication .................................................. 62

3.5

Macaque and human PBMCs fail to produce IFN- in response to B virus infected

fibroblasts ........................................................................................................................ 66
3.6

B virus replication is not sensitive to IFN- produced from virus exposed PBMCs ...... 73

3.7

Sensitivity of B virus replication in infected macaque and human cells to recombinant

IFN- 77
3.8

Medium from B virus exposed PBMCs activates the Type I IFN signaling pathway in

uninfected macaque and human fibroblasts...................................................................... 80
3.9

Cell-culture medium from PBMCs co-cultured with B virus infected human or macaque

fibroblasts activates Type I IFN signaling pathways in uninfected fibroblasts of each
respective species ............................................................................................................ 84

viii
3.10

B virus infection of macaque and human fibroblasts does not activate or block Type I

IFN signaling..................................................................................................................... 87
4

CONCLUSIONS................................................................................................................ 91

5

REFERENCES................................................................................................................... 94

6

APPENDIX .................................................................................................................... 121

ix
LIST OF TABLES
Table 1 Predicted Open Reading Frames of B virus ..................................................................6
Table 2 CDC B virus Working Group recommendations for post-exposure prophylaxis for
persons exposed to B virus ................................................................................................... 12
Table 3 TLRs and their associated PAMPs and DAMPs ........................................................... 14
Table 4 Raw data for B virus exposed pDCs of cytokine and chemokine production ............. 123
Table 5 Raw data for pDC cytokine and chemokine production in co-cultures ...................... 124

x
LIST OF FIGURES
Figure 1 Herpes simplex virus entry pathways.........................................................................3
Figure 2 Herpes virus replication cycle ....................................................................................4
Figure 3 Life cycle of herpes viruses in their natural hosts .......................................................9
Figure 4 Morphology of B virus infection in monkey epithelial cells .........................................9
Figure 5 B virus infection in monkey epithelial cells at different times post-infection ............. 10
Figure 6 MyD88-dependent TLR signaling pathway ............................................................... 15
Figure 7 TRIF-dependent TLR signaling pathway .................................................................... 17
Figure 8 HSV-1 inflammasome activation of NLRP3 and IFI16 by HSV-1 .................................. 18
Figure 9 Pathogen recognition of HSV ................................................................................... 20
Figure 10 The epidermal immune response to HSV-2 ............................................................ 22
Figure 11 The TLR7/9 signaling pathway in pDCs ................................................................... 26
Figure 12 Signaling pathways activated by the I-IFN receptor ................................................ 29
Figure 13 Classical JAK-STAT signaling pathway ..................................................................... 30
Figure 14 Human pDC purity after isolation from PBMCs. ...................................................... 45
Figure 15 The experimental design to measure the pDC response to B virus .......................... 46
Figure 16 Cytokines produced from B virus-exposed pDCs ..................................................... 53
Figure 17 Chemokines produced from B virus-exposed pDCs ................................................. 57
Figure 18 B virus titers in human fibroblasts ......................................................................... 59
Figure 19 IFN- production from pDCs is inversely correlated to virus within infected cell
lysates ................................................................................................................................. 62
Figure 20 pDCs do not support productive B virus infection ................................................... 66
Figure 21 IFN-production from B virus-exposed human and macaque PBMCs ..................... 72

xi
Figure 22 Infectious B virus contained in supernatants/cells of B virus infected human and
macaque fibroblasts............................................................................................................. 73
Figure 23 B virus exposed PBMC supernatants do not reduce B virus titers in fibroblasts ....... 77
Figure 24 B virus titers are unaffected by recombinant IFN- ................................................ 79
Figure 25 Medium from PBMCs exposed to B virus activates Type I IFN signaling in uninfected
fibroblasts ........................................................................................................................... 84
Figure 26 Supernatants from PBMC co-cultures activate Type I IFN signaling in uninfected
fibroblasts ........................................................................................................................... 87
Figure 27 B virus infection does not activate Type I IFN signaling in human or macaque
fibroblasts ........................................................................................................................... 88
Figure 28 B virus does not block the activation of the Type I IFN signaling pathway in macaque
or human fibroblasts ............................................................................................................ 90
Figure 29 Working model of the role of pDCs in B virus infection ........................................... 93
Figure 30 Donor response to CpG ....................................................................................... 121
Figure 31 Verification of fibroblast isolation and purity from macaque whole skin biopsies . 121
Figure 32 B virus kinetics in macaque and human fibroblasts .............................................. 122

xii
LIST OF ABBREVIATIONS

Ag: antigen
AIM2: absent in melanoma 2
ANOVA: analysis of variance
APC: antigen presenting cell
ASC: apoptosis associated Speck like protein containing a carboxy terminal
CARD
ATP: adenosine triphosphate
BDCA: blood dendritic cell antigen
BV: B virus, Herpes B virus
c-GAMP: cyclic guanosine monophosphate adenosine monophosphate
c-GAS: c-GAMP synthase
CARD: caspase activation and recruitment domain
CD: cluster of differentiation
CDC: Center for Disease Control
CNS: central nervous system
CpG/ CpG ODN: unmethlyated C+G DNA oligonucleotides
DAI/ZBP1: DNA dependent activator of IFN regulatory factors
DAMP: damage associated molecular pattern
DC: dendritic cell
DDX: DexD/H box
DMEM: Dulbecco's minimal essential media
DMSO: dimethyl sulfoxide
DNA-PK: DNA dependent protein kinase C
DNA: deoxyribonucleic acid
DRG: dorsal root ganglia
ECL: enhanced chemiluminescence
ECM: extracellular matrix
EDTA: Ethylene diaminetetra acetic acid
ELISA: enzyme-linked immunosorbent assay
FBS: fetal bovine serum
G-CSF: granulocyte colony stimulating factor
GAPDH: glyceraldehyde 3-phosphate dehydrogenase
GM-CSF: granulocyte macrophage colony stimulating factor
gX: glycoprotein X
HFF: human foreskin fibroblasts
HIV: human immunodeficiency virus
HMBG1: non-histone chromatin associating protein high mobility group box 1
HSP: heat shock protein
HSV: herpes simplex virus
HVEM: herpesvirus entry mediator
IC50: half maximal inhibitory concentration
ICOS: Inducible T-cell co-stimulator
ICP0: infected cell protein 0

xiii
IFI16: IFN  inducible protein 16
IFN: interferon
IFNR: Type I inferferon receptor
Igs: immunoglobulins
IKK: inhibitor of kappa light polypeptide gene enhancer in B cells, kinases
IL-1R: interleukin 1 receptor
IL: interleukin
ILT: immunoglobulin like transcript
IP-10: interferon  induced protein 10
IRAK: IL-1R kinase
IRF: interferon regulatory factor
ISGF: interferon stimulated gene factor
JAK: janus kinase
LGP2: laboratory of genetics and physiology 2
LPS: lipopolysaccharide
MCL: mock cell lysate
MDA5: melanoma differentiation associated protein 5
MEM: minimal essential media
MHC: major histocompatibility complex
MIP: macrophage inflammatory protein
MOI: multiplicity of infection
MyD88: myeloid differentiation primary response protein 88
NETS: neutrophil extracellular traps
NFB: nuclear factor kappa B
NK: natural killer cell
NLR: nucleotide oligomerization and binding domain (NOD) like receptor
NOD: nucleotide oligomerization and binding domain
NS: not significant
PAMP: pathogen associated molecular pattern
PBMC: peripheral blood mononuclear cell
PBS: phosphate buffered saline
PCR: polymerase chain reaction
pDC: plasmacytoid dendritic cell
PFU: plaque forming units
PILR: paired immunoglobin-like type 2 receptor alpha
PNS: peripheral nervous system
PRR: pathogen recognition receptor
RANTES: regulated on activation, normal T cell expressed and secreted
RBC: Red blood cell
RIG I: retinoic acid-inducible gene 1
RLR: retinotic inducible gene I (RIG-I) like receptor
RMF: rhesus macaque fibroblasts
RNA: ribonucleic acid
ROS: reactive oxygen species
SDS: sodium dodecyl sulfate
SEM: standard error mean

xiv
STAT: signal transduction activator of transcription
STING: stimulator of IFN genes
SUP: supernatant
T reg: T regulatory cell
TANK: TRAF family member associated NFB activator
TBK: tank binding kinase
TH: T helper
TICAM1: toll-like receptor adaptor molecule 1
TIR: toll/interleukin 1 receptor
TIRAP: TIR associated protein
TK: thymidine kinase
TLR: toll-like receptor
TNFR: tumor necrosis factor receptor
TRAF6: TNFR associated factor 6
TRAM: TRIF related adaptor molecule
TRIF: TIR domain containing adaptor protein inducing IFN

1
1

1.1
1.1.1

INTRODUCTION

Literature Review
B virus
B virus, or Macacine herpesvirus 1, formerly known as Cercopithicene herpesvirus 1, was first

discovered in 1934 when a doctor named Dr. William B. Brebner, was exposed to contaminated tissue
during necropsy of a seemingly healthy macaque. Dr. Brebner showed relatively mild symptoms early in
infection until day 10, where symptoms of central nervous system involvement were apparent. His
symptoms became increasingly worse and he succumbed to infection 15 days after the onset of neurological involvement. Post-mortem analysis indicated death due to acute disseminated disease and encephalomyelitis. Frederick Gay and Margaret Holden were one of two groups to first to identify the
agent as viral by injecting brain and spinal cord suspensions from Dr. Brebner into rabbits. The disease in
rabbits mimicked that of the disease in Dr. Brebner, although the rabbits succumbed in four to five days
post-infection. They designated the agent W virus [1, 2]. Colleagues within their same department, Drs.
Sabin and Wright, also identified the agent as a herpes virus around the same time, described the same
disease in rabbits and designated it B virus [3].
B virus has a linear double-stranded DNA genome of 157 kpb [4], although previous studies prior
to sequencing reported the length at 162.5 kbp [5] and 165 kbp [6] with 74.5% G+C composition [4]. The
genome is surrounded by an icosadeltahedral capsid with T=16 symmetry and a diameter of about 40nm
[7], which is surrounded by tegument proteins derived from host cell protein as well as virally encoded
proteins. The tegument is surrounded by a double-membrane obtained from the viral glycoprotein
studded host plasma membrane following exocytosis from the cell. The complete virus particle is approximately 160-180 nm in diameter [8].
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The B virus genome is predicted to encode up to 74 proteins [4]. At least 11 of these have been
identified as viral glycoproteins [9]. Genome sequence analysis predicted the presence of these eleven
glycoproteins as homologs of HSV-1 and HSV-2: gL [4, 10, 11], gM [4, 11], gB [4, 11], gC [4, 11], gH [4,
11], gG [4, 10, 12], gJ [4, 10, 13], gD [4, 10, 13], gL [4, 10], gE [4, 10], and gK [4, 11]. Recombinant proteins have been produced for gB, gC, gD gE and the secreted and membrane-associated segments of gG
[14].
B virus enters target cells primarily by fusion as well as receptor-mediated endocytosis, similar
to HSV-1/2 (Figure 1) [15] and I. Patrusheva, et al, unpublished raw data. B virus uses the common entry
receptors as HSV-1/2, heparan sulfate and nectin-1, but does not use the paired immunoglobulin like
receptor- (PILR-) or herpesvirus entry mediator (HVEM) [16]. It has also been shown that B virus can
use other receptors in addition to these, which may shed some light on the pathogenesis of B virus in
humans (I. Patrusheva, et al, unpublished raw data). Recent data has shown that gD is not required for B
virus entry into certain cells types, which is a unique difference between B virus and the human simplex
viruses to which it is closely related (I. Patrusheva, et al, unpublished raw data). Figure 1 is a working
model demonstrating the known mechanisms of entry for HSV, some of which are shared by B virus.
B virus, like all herpes viruses, replicates and assembles in the nucleus of infected cells. After virus entry into cells, the capsid and the tegument are transported to the nuclear pores where the DNA
genome is released into the nucleus. Viral gene transcription takes place within the nucleus and is mediated by host RNA polymerase II (pol II) along with viral and host transcription factors. As previously stated, B virus is predicted to encode about 74 genes (Table 1) [4]. B virus transcription occurs in a cascade
fashion beginning with the production of immediate early genes (), which mediate the transcription of
early genes) which then allow the transcription of the late genes () and DNA replication. The immediate early genes are transcribed without the production of newly formed virus proteins, so
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Figure 1 Herpes simplex virus entry pathways
HSV can enter cells a variety of ways depending on a number of cellular and viral factors [15].

must rely on host cell proteins and viral tegument proteins. A few examples of the immediate early
genes include infected cell protein 0 (ICP0) which has numerous functions, but a few include modulation
of host innate immune responses and promoting virus replication. The early genes products peak
around 5-7 h post-infection and include enzymes and DNA-binding proteins involved in replication including thymidine kinase (TK). Late gene transcription is dependent on virus replication and these gene
products are primarily involved in virion assembly and include the glycoproteins and capsid proteins
(Figure 2). The late genes can be divided into two sets of 1 and 2, depending on the timing of their
transcription. The 1 genes are referred to as leaky late genes, as expression in minimally affected by
inhibition of replication, while the 2 genes, or true late genes, are exclusively dependent on DNA replication as inhibition prevents their transcription [17]. There are only a small number of differences discovered thus far between B virus and HSV-1 and HSV-2 [4]. Two of these differences are noteworthy
and were discovered in our laboratory. One is the absence of a protein that has been implicated to have
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multiple functions, most predominantly neurovirulence, i.e., 34.5 [18, 19]. A second noted difference
was noted due to the absence 34.5, which also plays a role in blocking the innate defenses involved
with the activation of protein kinase RNA-activated (PKR), activated by Type 1 interferons. B virus has
selected for an alternative viral protein, Us11, to block this pathway, a function that can occur as a result
of early expression of B virus Us11 [20]. HSV Us11 proteins are not expressed until late in infection [21],
thus it appears that the novel temporal expression of B virus Us11 compensates for the lack of 34.5
homologs.

Figure 2 Herpes virus replication cycle
After entry into the cell and DNA delivery to the nucleus, the virus begins transcription of viral genes in a cascade of
, and  genes [22].
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The natural hosts for B virus are members of the Macaca species of Old World monkeys. The
disease within the natural host is relatively mild and similar to HSV-1/2 disease in humans, with occasional oral or genital lesions, although acute infection, as with HSV-1/2 can also occur with no apparent
lesions. B virus replicates in the mucosal epithelial cells, causing focal necrosis (lesion), where it gains
access to the peripheral nerves innervating the site of injury/entry. The virus travels within a neuron via
retrograde transport mechanism, and then establishes latency in the dorsal root or cranial ganglia. B
virus typically reactivates in macaques during mating season, monsoon seasons and during times of
stress, such as transport from facilities or the wild [23, 24] (Farah-Abraham et al., unpublished raw data).
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Table 1 Predicted Open Reading Frames of B virus
Genetic sequence analysis of B virus E2490 has predicted a number of genes and their functions by comparison with
HSV-1 and 2 [4].
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Table 1 (cont.) Predicted Open Reading Frames of B virus
Genetic sequence analysis of B virus E2490 has predicted a number of genes and their functions by comparison with
HSV-1 and 2 [4].

Upon reactivation, B virus travels via anterograde transport; and upon re-entry into the mucosal epithelium begins the replication cycle again and the production of infectious virions for infection of new hosts
or to freshen the supply of virus establishing latency in the dorsal root or cranial ganglia (Figure 3). Fatal
B virus infection in macaques is rare and is usually seen when a monkey is immunosuppressed [24, 25].
Other species of monkeys are also susceptible to fatal B virus infection, when they come into contact
with B virus shedding macaques, observed and reported in patas monkeys [26], colobus monkeys [26],
capuchins [2], and common marmosets [27] . Infection usually occurs when these monkeys are cohoused with infected macaques. B virus-infected cell cultures show the characteristic feature of herpes
viruses in that they form syncytia or multi-nucleated cells [28], particularly in epithelial cells derived
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from non-macaque species (Figures 4 and 5). This allows for the virus to maximize productivity and limit
the amount of cell-free virions.
In contrast, human infection (zoonotic) is fatal in up to 80% of cases if not treated quickly
enough following infection. B virus is the only herpesvirus thought thus far to be capable of zoonotic
infection [29]. Humans are typically infected from a bite or scratch from an infected monkey, or from
mucosal exposure to infected tissues or secretions. B virus replicates at the site of entry, in the periphery, causing edema and swelling and the characteristic herpetic lesions in some cases. B virus enters the
peripheral nerves innervating the site of injury or exposure, and travels to the sensory root ganglia. The
unusual and striking characteristic with human disease is that the virus travels beyond the DRG or cranial ganglia, and enters the central nervous system (CNS), where it travels to the brainstem via the dorsal
horn of the spinal cord or from the cranial ganglia, usually the ophthalmic branch of the trigeminal nerve
in the case of eye splash exposures. Whether virus-directed destruction or immune defenses mediate
the neurological symptoms seen with most fatal human infections remains unknown. Ascending paralysis results in respiratory failure. After B virus has entered the CNS, it is often impossible to curtail the
progression of disease. Reactivation from surviving human hosts has been observed in a few cases and
there has been one case of observed human-to-human transmission [30].
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Figure 3 Life cycle of herpes viruses in their natural hosts
Herpes viruses replicate in the periphery and gain access to the peripheral neurons innervating the area. The virions
are transported to ganglia where the virus can then establish latency. During reactivation, virus travels to the periphery to initiate lytic infection [31]. In human B virus infection, virus continues to the CNS, leading to encephalitis, encephomyelitis and death.

*

Figure 4 Morphology of B virus infection in monkey epithelial cells
An electron microscopic image of monkey epithelial cell (Vero) infected with B virus at 24h post-infection. There are
numerous budding particles on the cell surface () and the chromatin has dissipated (*) [28].
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Figure 5 B virus infection in monkey epithelial cells at different times post-infection
The characteristic syncytia caused by B virus infection in monkey cells at different times post-infection. (1) Normal uninfected cells, (2) at 6 h post-infection, the nucleolus begins to dissolve (), and (3, 4) at 36 h post-infection, multinucleated cells () are observed [28].

Diagnosis of B virus infection in humans and macaques is accomplished by detection of serum
antibodies reactive to B virus in Western blot assays and ELISA because virus is rarely shed peripherally.
Polymerase Chain Reaction (PCR) is used for the detection of B virus DNA, and cell-culture methods for
the detection of infectious particles, but these methods produce successful only when virus is being
shed into a sampled site, e.g., tears, saliva, genital secretions, etc. B virus can also be present in fomite
contaminants. Diagnosis in macaques can be difficult, because while the virus is latent, animals may not
have detectable levels of serum antibodies against B virus, particularly during primary infections. A difficulty in diagnosing humans is the fact that B virus antibodies cross react with HSV-1/2 antibodies, making a positive B virus diagnosis for co-infected individuals challenging [32-34].
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While there is no cure for B virus, rapid treatment following exposure can increase the survival
rate to nearly 80%. Of course, thorough and immediate cleansing is the key to the prevention of B virus
infection. Prophylaxis may have an added benefit of reducing the amount of virus that reaches the dorsal root or cranial ganglia [32]. After a fatal case of zoonotic infection resulting from an ocular splash in
1997, the Center for Disease Control (CDC) recommended the use of goggles and masks for individuals
working where macaques are or have been recently. The first few minutes after a potential B virus exposure are crucial to preventing disease. The person should wash the wound or site of exposure thoroughly for at least 15 min. Post-exposure prophylaxis is nearly always recommended (Table 2) [32]. Currently,
there are three available drugs for the treatment of B virus including acyclovir, valacyclovir, and
famciclovir, with acyclovir or valacyclovir preferred for patients who have not manifested CNS symptoms. Gancyclovir is recommended for zoonotic infections that have progressed to CNS symptoms. The
recommended serum levels to achieve for treatment are an IC50 of acyclovir at 18 g/ml (10-15 mg/kg
TID) [27]; gancyclovir at 9 g/ml (5-10 mg/kg TID) [27, 32]. Acyclovir is a guanosine nucleoside analog
that once phosphorylated by viral thymidine kinase can bind to viral polymerase, resulting in premature
chain termination of viral DNA [35]. Valacyclovir is a pro-drug of acyclovir, which is converted in the
body and famciclovir is the pro-drug of penciclovir [32]. Patient and physician preference dictate which
drug is to be used as there is no difference in their efficacy. Treatment is recommended for at least two
weeks, after which time if the patient remains asymptomatic, the drug is discontinued [32]. By the time
effective drug concentrations are sufficient to inhibit virus replication at the site of entry, any virus resulting from the exposure generally has time to enter innervating neurons. Thus, the goal of prophylaxis
is to minimize the amount of virus that populates the dorsal root or cranial ganglia.
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Table 2 CDC B virus Working Group recommendations for post-exposure prophylaxis for persons exposed to B virus
The CDC recommends prophylaxis after potential B virus exposure, depending on the circumstances of the situation:
if the monkey is infected, location of the injury and how quickly treatment was administered [32].

1.1.2

Immune Response to herpes viruses
The immune system is divided into two arms, the innate and adaptive immune systems. While

for simplicity of understanding they are often considered separate systems, it is important to remember
that the two arms communicate to help mount an effective immune response to a pathogen. Innate
immune responses are relatively non-specific that involve a number of cells, some of which include
monocytes, macrophages, dendritic cells, natural killer cells (NK), and neutrophils. An important consideration is that other cell types, such as cells within the mucosal and skin epithelium or non-professional
cells, also initiate innate responses, such as the production of cytokines and chemokines. Importantly,
these early innate responses also help to activate the adaptive arm of the immune response, including T
cells and B cells for effective control of the invading pathogen.
Cells can recognize a foreign pathogen through distinct pathogen-associated molecular patterns
(PAMPs) or damage-associated molecular patterns (DAMPs) by pathogen specific components or
through products of the damage they cause, respectively. Cells have specialized systems for the detec-
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tion of PAMPs/DAMPS called pathogen recognition receptors (PRRs). PRRs include RIG I-like receptors,
toll-like receptors (TLR), NOD-like receptors, C-type lectin receptors, and the DNA sensors.
1.1.2.1 Retinoic acid-inducible gene I-like receptors (RLRs)
The retinoic acid-inducible gene I (RIG I) like receptors (RLRs) include three known cytoplasmic
sensors: RIG-I [36], melanoma differentiation-associated gene 5 (MDA-5) [37] and laboratory of genetics
and physiology 2 (LGP2) [38, 39], which recognize virus-derived RNA. They are adenosine-triphosphate
(ATP)-dependent RNA-helicases that unwind dsRNA molecules. RIG-I recognizes short dsRNA structures
and 5’triphosphate ssRNA and MDA-5 recognizes longer and more complex RNA structures [40]. HSV
has been shown to activate the RLR pathway in mouse fibroblasts although the mechanism of action
was unclear [41], and recent studies have implicated cross-talk with other PRRs to induce a response to
HSV, and showed a requirement for HSV entry and replication [42]. Although the source of activation by
dsDNA viruses is unclear with respect to cytoplasmic RNA sensors, Weber et al, have shown that after
HSV infection, dsRNA does accumulate but the source of the RNA, whether cell-derived or from virus, is
undetermined [43].
1.1.2.2 Toll-like receptors
The toll-like receptors (TLRs) are the best characterized PRRs and recognize a diverse array of
PAMPs and DAMPs. Toll-receptors were first discovered in the Drosophila species and the mammalian
homologs were later identified as a crucial sensor in innate immune responses and referred to as Tolllike receptors (TLRs) [44]. Currently there are 12 identified TLRs in mammals of which TLRs 1-11 form
homo- or heterodimers. Upon binding by their PAMP or DAMP, TLRs initiate signaling events that lead to
immune gene activation and are either MyD88-dependent (Figure 6) or TRIF-dependent (Figure 7) [45].
TLR 1 is an extracellular PRR and recognizes lipoproteins when hetero-dimerized with TLR2. Extracellular
TLR2 can also form a dimer with TLR6 to sense lipoprotein PAMPs, and the DAMPS: heat shock proteins
(HSPs), the non-histone chromatin associating protein high-mobility group box 1 (HMGB1), and extracel-
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lular matrix (ECM). TLR3 is both extracellular and endosomal and recognizes dsRNA and mRNA. TLR4
recognizes lipopolysaccaride (LPS) and can detect a number of DAMPs, such as HMGB1, HSP, ECM, reactive oxygen species (ROS), defensins, amyloid B and ox-LDL. TLR5 detects bacterial flagellin. TLRs 7
and 8 form a dimer in the endosome for the detection of ssRNA. TLR9 is endosomal and detects unmethylated CpG motifs in host, viral, and bacterial DNA. Recently it is thought that TLR9 detects extracellular DNA because B cells exposed to extracellular self-DNA resulted in TLR9 activation [46]. Therefore, the route may be more important than the methylation state of the DNA. TLR 10 is non-functional
in humans, at least as of now. Lastly, TLR11 detects profilin-like molecules and uropathogenic bacteria
(Table 3) [45].
Compartmentalization of TLRs allows for specialized responses to pathogens. TLRs 1, 2, 4,and 5
are located on the cell surface, allowing for extracellular sensing of pathogens, and primarily detect
pathogen products such as, glycoproteins or membrane structures. The TLRs 3, 7, 8 and 9 are endosomal
allowing for intracellular sensing of pathogens by detection of bacterial or viral nucleic acids. Additional
cell types, namely the antigen-presenting cells (APC) are capable of taking up infected or necrotic cells,
and inducing endosomal immune responses to extracellular pathogens.

Table 3 TLRs and their associated PAMPs and DAMPs
TLRs recognize a number of PAMPs and DAMPs allowing for specialized detection and subsequent immune response
activation [45].
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TLR signaling is initiated by binding of the respective PAMP or DAMP to the TLR dimers. Upon
binding, TLRs 1,2, 7, 8, and 9 each use the myeloid differentiation primary response protein 88 (MyD88)
dependent signaling pathway (Figure 6) [45]. TLR3/4 signaling use a toll/interleukin-1 receptor (TIR) domain containing adaptor protein inducing IFN- (TRIF or TICAM1)-dependent pathway (Figure 7) [45].
These signaling pathways may differ slightly in specialized cell types.

Figure 6 MyD88-dependent TLR signaling pathway
TLRs 1,2, and 4-9 signal through a MyD88 signaling pathway. There are multiple signaling adaptors recruited upon ligand binding, and many mechanisms to limit TLR activation, both cellular and pathogen mediated. The end point of
TLR activation is increased gene expression of immune factors to recruit and activate immune responses [45].

The MyD88 dependent pathway is initiated by binding of the PAMP to the TLR dimers, which
then recruits the MyD88 adaptor molecule or the TIR-associated protein (TIRAP). These molecules asso-
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ciates with IL-1R associated kinases (IRAKS) and tumor necrosis factor receptor (TNFR)-associated factor
6 (TRAF 6). This results in the activation of the canonical inhibitor of kappa light polypeptide gene enhancer in B cells, kinases (IKK ) and subsequent nuclear factor B (NFB) activation. The TRIF depending signaling pathway, utilized by TLR 3 and 4, is activated upon dsRNA or LPS binding leading to the
recruitment of TRIF and TRIF-related adaptor molecule (TRAM), which then recruits TRAF family member associated NFB activator (TANK)-binding kinase (TBK1) and IKK and interferon regulatory factor
(IRF) 3 activation. These transcription factors then enter the nucleus to direct pro-inflammatory gene
activation and Type I interferon production that direct specific immune responses to a pathogen [45].
HSV has been shown to activate a number of TLRs. HSV can activate TLR2 through unknown
mechanisms in bone marrow-derived dendritic cells [47], microglia [48], Chinese hamster ovary cells
[49], and HEK293 cells [48, 50] transfected with TLR2. TLR2 is also know to sense several DAMPs, some
of which include HSP60 and 70 which are upregulated following HSV infection [51, 52]. HSV-2 infection
leads to the production of non-histone chromatin associating protein high mobility group box 1
(HMBG1) [53] , which is a known PAMP of TLR2 [54]. TLR3 has been shown to respond to dsRNA generated in the cytoplasm following HSV infection of fibroblasts, although the source of the RNA, whether
viral or host, is unclear. TLR3 deficient patients have a higher prevalence of HSV encephalitis, indicating
an important role for TLR3 mediated sensing in HSV infection [55]. TLR9 is a well-known sensor for HSV
DNA. Plasmacytoid dendritic cells, B cells and macrophages have been shown to sense HSV DNA through
TLR9 [56-59]. Although mice lacking TLR9 show a reduction in the production of Type I IFNs, virus control
is similar to control mice [56]. This indicates an important, however, non-exclusive requirement for TLR9
signaling during HSV infection but appears to play a role in limiting virus spread along with TLR2 [56, 60].
1.1.2.3 NOD-like receptors
Another PRR includes the nucleotide oligomerization and binding domain (NOD)-like receptors
(NLR). There are over 20 known NLR family members, although NLRP3 is the most widely studied.
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Figure 7 TRIF-dependent TLR signaling pathway
TLRs 3 and 4 are the only TLRs to signal using the TRIF adaptor. TLR4 can also use MyD88. Activation of TLR3 by dsRNA
leads to the recruitment of a number of cellular factors, leading to immune gene activation via NFB and IRF 3/7.
There are a number of ways to regulate TLR3 signaling, both cellular and pathogen mediated [45].

These receptors are characterized by a NOD motif, but also contain a variety of other activating domains
that are crucial for function. Once they are activated, NLRs expose effector domains that can recruit signaling molecules for initiation of immune gene activation. NLRs are activated by the binding of a variety
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of PAMPs: RNA or DNA; or damage associated molecular patterns (DAMPs): reactive oxygen species
(ROS), cathepsin B and K+ influxes. NLR activation leads to the modulation of signaling pathways directing immune responses, such as the NFB, MAPK, the Type I IFN pathway, and activation of the inflammasome. In the case of herpes viruses, varicella virus, which is the causative agent of chicken pox, activates NLRP3 through unknown mechanisms [61]. Additionally, HSV has been shown to activate the
NLRP3 containing inflammasome at early times post-infection in human foreskin fibroblasts (HFF; Figure
8) [62].

Figure 8 HSV-1 inflammasome activation of NLRP3 and IFI16 by HSV-1
HSV-1 has been shown to activate NLRP3 through unknown mechanisms, and IFI16 though nuclear and cytoplasmic
dsDNA. Activation of both pathways lead to initiation of the inflammasome and IL-1 gene expression, but HSV-1
blocks mature IL-1 secretion [62].

1.1.2.4 DNA sensors
The last PRR to be discussed here are the recently identified DNA sensors. There are currently 10
known sensors of DNA, including DNA-dependent activator of interferon-regulatory factors (DAI or
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ZBP1), RNA pol III, interferon-gamma-inducible protein 16 (IFI16), the DExD/H box helicases DDX60,
DHX9, DDX41, and DHX36, Ku70, absent in melanoma 2 (AIM2) and the cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (c-GAS), to name a few.
DAI was the first cytoplasmic DNA sensor identified for HSV [63], although knockdown of DAI did
not completely abrogate the response to dsDNA, indicating the presence of other sensors [64]. Recent
studies indicate that HSV-2 can activate DAI in vaginal epithelial cells [65].
RNA pol III recognizes cytoplasmic dsDNA by creating RNA intermediates that can be recognized
by RIG-I, at least in human 293T cells and in mouse cells [66, 67], but blocking RNA pol III did not inhibit
cytokine production in human macrophages, thus the role of RNA pol III in DNA sensing is questionable
[68].
The molecule IFI16 is a DNA sensor that is commonly activated following HSV infection. It can
sense nuclear DNA and can shuttle between the cytoplasm and nucleus [69-78]. It has been shown to
detect DNA in a number of cell types including: fibroblasts [62], epithelial cells [72], human neutrophils
[77] and dendritic cells [75]. IFI16 has been shown to detect HSV DNA in HFFs [79] and monocytederived macrophages [76] and has been shown to induce inflammasome activation in HFFs at early
times after infection, after which it is later blocked [62].
The DExD/H box helicases bind directly to DNA nucleotides and include DDX60, DHX9, DDX41,
and DHX36, to name a few. These helicases signal through different mechanisms depending on the helicase involved. For example, the DHX36 and DHX9 signal through MyD88 [80], while many others signal
through a complex with stimulator of interferon genes (STING) and TBK [78]. More recently another sensor of DNA has been identified as c-GAS [81, 82], which can bind directly to DNA and form a complex
with STING to mediate IFN- production.
AIM 2 is a member of the PYHIN family, in which humans have 4 members, including IFI16. AIM2
binds DNA within the cytoplasm by the HIN domain independent of the sequences, and interacts with
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the apoptosis-associated speck-like protein containing a carboxy-terminal CARD (ASC) component to
activate the inflammasome [83-85]. AIM2 has also been identified as a DNA sensor for HSV and is limited to cytoplasmic DNA [71, 84].
Ku70 is a part of the DNA-dependent protein kinase (DNA-PK) complex along with Ku80 [86],
and is involved in nuclear processes such as non-homologous end-joining DNA repair, V(D)J recombination, and telomerase maintenance [87]. It has also been shown to mediate DNA sensing in the cytoplasm
in HEK293T cells and mediates IFN  production [88, 89]. Ultimately, with all of the PRRs, the goal of
responding to pathogens is to mount an effective immune response to limit infection and spread and it
is no different for HSV in the natural host (Figure 9).

Figure 9 Pathogen recognition of HSV
HSV can be detected by many PRRs including TLRs 2,3,and 9, and the DNA and RNA sensors. The pathways associated
with HSV-1 recognition lead to anti-viral cytokine and chemokine expression [90].

1.1.2.5 Innate immune cells
Now that we understand how cells are able to sense an invading pathogen, it is important to
understand the contribution of the many different cell types involved in innate immune responses and
how their functions help shape an effective adaptive immune response. A few key players in innate im-
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munity include the non-professional cells, such as the endothelial or epithelial cells, which are usually
the primary targets of infection, and the professional cells such as dendritic cells, monocytes, macrophages, natural killer cells, and neutrophils.
In the case of HSV, the mucosal epithelium or skin epithelium is crucial in sending those first signals that something is wrong (Figure 10). Keratinocytes and fibroblasts are the skin cells used for in vitro
HSV studies of primary human infection when clinical samples are unavailable. Primary cell production
of cytokines and chemokines is crucial for mounting an initial response to a pathogen by recruiting and
activating effector immune cells. Fluids from recurrent herpetic lesions on day 1 contained mostly IL-1,
followed by IL-6, IL-10, IL-1 and IL-12, while on day 3, contained mostly IL-6, followed by IL-1, IL-1,
TNF- while IL-10 levels remained unchanged. Chemokines were also produced from recurrent lesions
and contained mostly MIP-1, followed by MIP-1 and RANTES [91]. Keratinocytes are one of the first
sites of primary HSV replication, and despite rapid cell destruction after HSV infection, these were
shown to be a source of IL-12, IL-10, MIP-1, MIP-1 and RANTES on day 3 after HSV infection, and IL1, IL-1 and IL-6 after 6 days [91]. Additional studies showed that in vitro HSV infection of keratinocytes increased expression of the interferons and , TNF-, G-CSF, GM-CSF, IL-3 and several growth
factors [92], indicating an important role for these cells in sending the first signals for immune activation. Fibroblasts are the primary cells comprising the dermal layer of skin and are also a source for in
vitro studies with HSV. Very little data exist on the cytokines and chemokines produced after infection of
these cells. Recent studies for NLR and DNA sensor activation showed a failure of HFFs to respond to
HSV with the production of IL-1[62], but also showed an increase in IFN- transcripts after HSV infection [79]. Additionally, recent studies in our lab showed that HFFs failed to secrete any cytokines or
chemokines following HSV-1 infection including: eotaxin, G-CSF, GM-CSF, IFN-α2, IFN-γ, IL-10, IL-12
(p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIP1α, MIP-1β, TNF-α, or TNF-β (M. Vasireddi et al., unpublished raw data).
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Figure 10 The epidermal immune response to HSV-2
HSV-2 infection initiates in the keratinocytes which respond to virus through the production of many cytokines and
chemokines, which recruit a number of innate and adaptive immune cells [93].

Following the signals received from infected primary cells, innate effector immune cells are recruited
into action during infection. The first cells to enter HSV lesions appear to be neutrophils. Neutrophils,
whose primary function is to destroy pathogens through the production of large amounts of ROS and
cytotoxic granules within the phagosomes, are specialized innate immune cells that circulate in the
blood. More recently, neutrophils have been shown to expel nuclear complexes containing DNA and
granular proteins, as well as LL37 called NETs, providing another means of microbial protection [94, 95].
Neutrophils also help shape the immune response through the production of cytokines that direct antibody production by B cells [96-98], can directly activate T cells through their expression of activating
receptors [99, 100] and MHC II [100] as well as transport antigen from the dermis to the lymph nodes
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[101-104]. Neutrophils can activate pDCs through the production of NETs [105] and coordinate with DCs
to activate NK cells [106, 107]. Neutrophils have very tightly regulated systems for migration [108, 109]
and the production of granules [110]. Neutrophils are well known for their ability to destroy extracellular bacteria and fungi, but more recently have been shown to play a role in anti-viral immunity to HIV
[111] and poxvirus [112] through the production of NETs.
Additional cell types involved in the innate immune response to herpes viruses include macrophages, natural killer cells, dendritic cells, including myeloid dendritic cells, plasmacytoid dendritic cells,
skin dendritic cells, the Langerhan cells and dermal dendritic cells. Other subsets of dendritic cells are
present within lymphatic tissue are also important for immunity against herpes viruses.
Adaptive immune responses are initiated through the activation signals of innate immune cells.
B cells and T cells are the most common cell types associated with adaptive immune responses. T cells
can be divided into a number of subsets to include CD4+ T cells, CD8+ T cells, regulatory T cells, and suppressor T cells. The subsets of T cells can be distinguished by their transcription factor expression. Typically CD4+ T cell functions are divided into multiple subsets including two of which are the T helper-1
(TH1) or T helper-2 (TH2) responses. Their responses are called into play by the specific cytokines produced by innate cells as well as the T cells themselves, and are associated with the activation of the different subsets of T cells. TH1 is often referred to as the cell-mediated branch of adaptive immunity and
usually leads to the activation of cytotoxic CD8+ T cells, which leads to cell-mediated cell death, while
the TH2 refers to the antibody-mediated branch and typically leads to the activation of B cells for the
production of antigen specific immunoglobulins (Igs). It is important to note that many of the other Tcell subsets likely play additional roles at different times during infection.
1.1.2.6 Plasmacytoid dendritic cells
Plasmacytoid dendritic cells are a specialized group of lymphoid-derived dendritic cells that recognize bacterial and viral genomes through their exclusive expression of TLRs 7 and 9 [113-115].
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Plasmacytoid dendritic cells are identified based on surface phenotypic markers, specifically CD4+,
CD45RA+, IL3R (CD123)+, ILT3+, ILT1-, CD11c-, lineage-, BDCA-2, BDCA-4, CD4+, [116]. The primary
function of pDCs is to produce large amounts of Type I IFNs, including 13 subtypes of IFN- and IFN-
and Type III IFNs such as IFN-, but pDCs do not make IFN-, the only type II IFN. pDCs can also make
tumor necrosis factor- (TNF-), IL-6, IL-1, and several chemokines such as MIP-1 , and IL-8 to
recruit and activate a number of effector immune cells to the sites of infection [117-121]. Additionally,
pDCs are capable of presenting antigen to T cells, although this is not their primary role. pDCs can be
found in the skin, in peripheral blood, and in the lymph nodes [122] .
Plasmacytoid dendritic cells were first described in the 1950s by pathological examination of
lymph node and splenic tissues, as cells with a plasma cell-like morphology [123]. Decades after their
initial identification, when more advanced cell immunology assays were developed, these cells were
designated plasmacytoid T cells [124, 125], or plasmacytoid monocytes [126], based on the cell surface
phenotypes. In the 1980’s a very similar cell-type, with plasma like morphology, was designated as the
natural interferon-producing cell [127], because they produced large amounts of IFNs in response to
virus infections and they were distinct from T cells, B cells, monocytes and NK cells [127-130]. Only very
recently, in 1997, were these cells shown to be of dendritic cell origin and were called DC2 based on
their ability to differentiate into TH2 DCs [125]. In 1999, the natural interferon-producing cell was confirmed to be the same as the plasma-like DC2 and thus designated plasmacytoid dendritic cells (pDC)
[116, 126].
The pDCs exclusively express TLRs 7 and 9 to allow the detection of viral nucleic acids. A commonly used positive control for TLR9 activation is synthetic single-stranded DNA containing unmethlyated phosphorothioate-linked CpG motifs (CpG; CpG ODN) [131-134]. These TLRs are endosomal,
activated in response to foreign DNA in most cases. TLRs 7 and 9 share a signaling pathway that is mediated by MyD88. Following activation, a signal transduction complex is formed in the cytoplasm and is
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composed of many different proteins, including MyD88, IRAKs, TRAFs, and IRF7 [115, 135-137] (Figure
11). IRF7 is constitutively expressed in pDCs, along with IRF4, and IRF8 [138], due to lack of translational
repressors (4E-BPs) [139], and upon activation is rapidly translocated to the nucleus for IFN transcription
initiation when TLR signaling is initiated by the early endosome. This signaling complex is also capable of
activating the NFBs [140] and MAP kinases [141] by engagement of ligands in the late endosome to
direct the activation of pro-inflammatory cytokine and chemokine genes and co-stimulatory molecule
expression [134]. The constitutive expression of the IRFs allows for a rapid IFN response independent of
the IFNR feedback that most other cells require [142]. IRF 8 amplifies the IFN response during the second phase of IFN transcription and IRF 4 is a negative regulator of proinflammatory cytokine production
by interacting with MyD88 [143], but does not interfere with IRF7-dependent IFN responses.
Upon activation pDCs undergo maturation in which they downregulate IFN- and proinflammatory cytokine production and up-regulate co-stimulatory molecules for antigen presentation
and T cell activation, such as CD40, CD80, CD86, CD83, ICOS-ligand and OX40 ligand [144]. pDCs are efficient activators of T cells [115, 122, 125, 145-148], although they are less efficient than the conventional
DCs due to the short half life of MHC II on the cell surface and the rate at which they take up antigen
[149]. pDCs have been shown to activate T cells through direct MHCII expression, but also through transfer of Ag to lymph node resident DCs for cross-presentation to CD8 T cells in cutaneous HSV-1 infection
in mice [150].
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Figure 11 The TLR7/9 signaling pathway in pDCs
Viral nucleic acids are taken into pDCs by endocytosis and transported to the endosomes for activation of TLR7/9. This
pathway is mediated by MyD88 and triggers a signaling cascade that leads to a complex formation consisting of
IRAK1, IRAK4, TRAF3/6, which activate constitutive IRF7 to induce IFN gene transcription. Additional signaling molecules can then activate NFBs and MAPKs to induce pro-inflammatory cytokine production and co-stimulatory molecule expression [151].

pDCs respond robustly to HSV-1 through the production of Type I IFNs [41, 56, 57, 122], and
thus HSV-1 is commonly used as a positive control for pDC activation and was used in the experiments
presented in this dissertation. HSV contains numerous CpG motifs that can interact with TLR9 [152] to
activate pDCs via TLR 9 [42, 56, 57], and independently of TLR 9 [153]. It has been shown that pDCs are
important in in vivo studies as they are recruited to active HSV-2 lesions and are important for recruiting
and activating T cell responses [122]. Also, antibody depletion studies in mice showed that pDCs, dispensable in controlling systemic infection, were necessary for IFN- production by cytotoxic T cells. Absence of pDCs extended the time for virus clearance [150]. pDC-induced IFN- has been shown to activate HSV specific CD4+T cells in mice for the production of IFN- and IL-10 [154]. This IFN has also been
shown to induce the migration of T cells and NK cells through the production of chemokines [58]. pDCs
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are also important in reducing viral titers in HSV-2 infected mice since pDC depleted mice showed worse
survival than normal mice [155]. Additional studies in mice showed that pDC depletion reduced the systemic IFN- and pro-inflammatory cytokine production, and subsequent activation of NK cells and CD8+
T cell responses to HSV-1. But for localized infections, pDCs did not reduce the viral burden or survival in
subcutaneous HSV-1 or intravaginal HSV-2 infection [156]. In vitro studies of human pDCs showed that
HSV-1 activated pDCs stimulated CD4 T cells to express perforin and granzyme, and produce IL-10 and
IFN- [157]. Also, Kittan et al. reported patients suffering from HSV retinal necrosis had reduced pDC and
CD8 T cell numbers [158], although Moss et al. found no correlation with circulating pDC numbers and
the clinical severity of HSV-2 infection [159].
Massive production of IFNs and pro-inflammatory cytokines from pDCs helps to shape both the
innate and adaptive immune responses to pathogens. pDC-induced IFN- and TNF- promotes autocrine survival as well as survival and maturation of bystander pDCs [154]. Cytokines from pDCs can robustly recruit and activate NK cells for lysis of infected cells [56, 58, 160, 161]. pDC induced cytokines
also shape the immune response by activating monocytes to increase TLR7 expression and surface expression of pDC markers [161, 162], and can induce monocytes to produce IFN- in response to HSV
[163] as well as induce IP-10 production from monocytes to recruit other effector cells [164]. pDCs can
also shape the antibody response by IFN- induced expression of B cell activating factor (BAFF) on mDCs
[165], inducing B cell differentiation into antibody secreting plasma cells through the production of IFN and IL-6 [166], and can induce class-switching of plasma cells [167]. Overall, the pDCs response is important for combating pathogens through the production of IFNs and cytokines and chemokines for the
recruitment and activation of effector immune cells, all of which contribute to the overall host response
to a pathogen.
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1.1.3

Type I Interferon Pathway
Interferon was first discovered in 1957 when two researchers, Isaacs and Lindenmann, were ex-

ploring a new concept of viral interference. This was the first time a soluble factor was identified and
shown to provide protection to uninfected cells [168]. The Type I Interferon pathway is important for
the induction of an antiviral state within infected hosts. This pathway is initiated by a number of PRRs,
such as TLRs, RLRs, DNA sensors, nucleic acid sensing molecules, such as RIGI, MDA5 for RNAs and DAI
and IFIs for DNA detecting the invading pathogen, as discussed previously. Activation of the PRRs leads
to the recruitment and activation of signaling molecules that are specific for antiviral genes to control
the invading pathogen. The downstream activation targets differ, but ultimately activate interferon
stimulated gene factors (ISGFs) that can direct interferon-stimulated gene (ISG) transcription. These
genes are then transcribed and the proteins act at different stages of virus replication and gene transcription. A specific gene activated through any of these pathways is type I interferons  and . There
are five types of Type I IFNs, IFN-, IFN-, IFN-, IFN-, and IFN-Of these, IFN-and  are the main
subtypes of interest in antiviral immunity. There are 13 subtypes of IFN-1245678,
101314,16,17,and21 in humans and only one of IFN- [169-171].These two IFNs bind to
a common receptor, the IFNR, which is composed of two subunits of IFNR1 and IFNR2. These complexes dimerize and can be bound by the different subtypes of Type I IFNs, which triggers a signaling
cascade. The signals are mediated by a number of adaptor molecules, depending on the activating ligands (Figure 12) [172]. Ultimately, these pathways culminate in the activation of interferon-stimulated
genes, such as IFN-/, pro-inflammatory cytokines, protein kinase R (PKR), MDA-5, 2’5’oligoadenylate
synthase (OAS), and IRFs [173]. These gene products then act by a number of mechanisms to establish
an anti-viral state within the host.
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Figure 12 Signaling pathways activated by the I-IFN receptor
Signaling pathways followed by the binding of ligands for the Type I IFN receptor culminates in activation of
the JAK/STAT pathway, leading to the recruitment of several adaptor molecules such as IRFs, which can
then enter the nucleus to direct the transcription of many ISGs [172].

For this dissertation, the focus will be on the pathway mediated by IFN-, or the Janus activated
kinase-signal transducer and activation of transcription (JAK/STAT) pathway. IFNR1 is constitutively
associated with tyrosine kinase 2 (TYK2) and IFNR2 is associated with JAK1 [174-176]. Upon receptor
binding by IFN-/, JAK1 and TYK2 are transphosphorylated and then the JAKs phosphorylate the IFNR
subunits on tyrosine residues [177, 178]. These phosphate residues allows for docking by the recruited
STAT molecules via the src-homology domains (SH2) [174, 179]. Depending on the signals received, the
JAK1 and TYKs can recruit several different STAT molecules. There are currently 6 STAT molecules activated after Type I IFN binding, including STATs 1-6, although expression of some isoforms are limited to
certain cell types [174, 179-186]. Once recruited to the receptors, STATs are phosphorylated by JAKs.
Activated STATS can form homodimers such as STAT1, STAT3, STAT4, STAT5, and STAT6 and heterodimers of STAT-1/2, STAT1/3, STAT1/4, STAT1/5, STAT2/3, and STAT5/6 [179-181, 187, 188]. For STAT1
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and STAT2, the activating phosphorylation occurs on a single tyrosine residue, at Y701 and Y690, respectively. STAT1 is also phosphorylated at Ser 727, which is required for optimal gene transcription, but not
for nuclear translocation [189, 190]. Activated STAT1/2 then associates with IRF9 (ISGF3 complex). The
ISGF3 enters the nucleus and binds to interferon stimulated regulatory elements (ISRE) on DNA to direct
ISG transcription (Figure 13) [174, 179-181, 185, 191]. Within the nucleus STATs interact with a series of
co-activators such as p300 and cAMP-responsive element binding proteins (CREB) binding protein (CBP),
which help to regulate chromatin remodeling for access to promoters of ISGs [192-194].

Figure 13 Classical JAK-STAT signaling pathway
The binding of IFN- or  activates the JAK-STAT signaling pathway, leading to the activation and recruitment of STAT
homo- or heterodimers that complex with IRF9 and enter the nucleus to bind to ISRE direct ISG transcription [194].

Herpesviruses are known to block many steps of the Type I IFN pathway. HSV can block the induction of the IFN pathway by blocking protein kinase R (PKR) activation by US11 late in infection, an
RNA binding protein [195-199], or by 34.5 early in infection forming a complex with protein phosphatase 1 (PP1) to reverse PKR activation [196, 200, 201]. HSV also interferes with the IFN signaling pathway
by blocking the activation of JAK via ICP0 [201, 202], and prevents the nuclear translocation of STAT by
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ICP27 [203]. Furthermore, US3 hyperphosphorylation of IRF3 prevents nuclear translocation [204], and
blocks ISG mRNA induction [205], although this has recently been challenged [206]. Very recently, VP-16
has been shown to interfere with IRF-3 mediated gene activation by disrupting the interaction of IRF3
and the co-activator, CREB-binding protein (CBP) [207]. HSV can also block the signaling pathways induced by secreted IFNs, such as preventing the phosphorylation of JAK/STATs in the IFN signaling pathway, although this is dependent on cell type [208] as well as inducing the suppressor of cytokine signaling (SOCS), which binds to JAKs to block their activation [209] to limit ISG activation against HSV.
1.2

Research Goals
The goals of this dissertation were to explore the interferon response within the context of the

foreign and natural hosts to determine whether this response may correlate with the pathogenesis of
infection, or plainly said, why macaques live, having a robust immune response and humans die with
little-to-no defense responses. Because the interferon pathway is so crucial to the development of an
antiviral state, either as a direct effect on infected cells or through indirect activation of effector functions of immune cells, I aimed to characterize this response in both hosts. This dissertation was designed
to test the hypothesis that B virus modulates the IFN response during zoonotic infection by blocking
pDC activation and subsequent IFN signaling pathways to circumvent host defenses, while these
pathways remain intact in the macaque hosts. To test this hypothesis, I first looked at the plasmacytoid
dendritic cell response within the human host using a cell culture model system to mimic events that
occur when B virus infects skin or mucosal cells at the site of entry. These are one of the primary target
cells crucial for initiating the interferon response as well as for helping to shape the development of
adaptive immunity, both of which appear to be dysfunctional during human B virus infection. Next, I explored the macaque immune response to B virus infection ex vivo to determine PBMC response to B virus, as it was not possible to isolate pDCs from macaques due to lack of specific reagents to enrich these
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cells. Further, we studied the interferon-signaling pathway within fibroblasts, from both humans and
macaques, to identify differences between the two host cell responses at the primary sites of infection.
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2.1

MATERIALS AND METHODS

Cells and Viruses
B virus stock (strain E2490; passage 74; originally a gift from E. Hull) was generated by passage

in Vero E6 cells (lot CCL-81; ATCC, Manassas, VA) in Dulbecco’s modified Eagle’s medium (DMEM; Mediatech, Inc; Manassas, VA) supplemented with 2% fetal bovine serum (FBS; Atlanta Biologicals, Norcross,
GA). Virus stocks were obtained by one round of freeze/thawing at -80C and were clarified by centrifugation at 1000 rpm for 10 min at room temperature. Virus titers were determined by standard plaque
assay. Virus stocks were kept at -80C until use. All experiments conducted for this dissertation were
done using the same stock of the P74 strain of B virus E2490. All experiments with B virus were done in a
CDC-Registered BSL-4 laboratory in compliance with the Department of Homeland Security’s regulations
for Select Agents, in effect during most of this project.
Herpes simplex virus-1 (strain MacIntyre; passage 7; lot VR-539; ATCC, Manassas, VA) was generated by passage in Vero E6 cells (lot CCL-81; ATCC, Manassas, VA) in Dulbecco’s modified Eagle’s medium (DMEM; Mediatech, Inc; Manassas, VA) supplemented with 2% fetal bovine serum (FBS; Atlanta
Biologicals, Norcross, GA). Virus stocks were obtained by one round of freeze/thawing at -80C and were
clarified by centrifugation at 1000 rpm for 10 min at room temperature. Virus titers were determined by
standard plaque assay. Virus stocks were kept at -80C until use.
2.2

Virus Stocks and Plaque Assay
Virus stocks were generated in Vero E6 cells in confluent roller bottles. Cells were infected at an

MOI of 0.01 for 48 h. For collection, the roller bottle was shaken or scraped to dislodge any remaining
cells then transferred to a 50 ml conical tube and centrifuged for 10 min at 1000 rpm. Supernatants
were discarded and the pellet was resuspended in 5 ml of diH20 with 2X protease inhibitor. Virus stocks
were frozen and thawed once prior to aliquoting. Virus stocks were stored at -80C until needed.
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Virus titers were determined by standard plaque assay. Briefly, Vero E6 cells were seeded into
12-well plates so that they were 90% confluent on the day of the experiment. Ten-fold serial dilutions
were made in plain DMEM and 100 l of each dilution was added to the respective wells. Virus was allowed to adsorb for 1 h at 37C at which time the lysate was removed and 1 ml of 0.8% methylcellulose
was added to each well. Cells were cultured for 48 h at 37C. For collection, wells were washed with PBS
until all the methylcellulose was removed and 100% methanol was added to each well for 15 min. Plates
were dunked out, rinsed and staining with 0.1% crystal violet. Plaques were counted and final titers
were determined.
2.3

Rhesus Macaque Fibroblast Isolation and Maintenance
Rhesus macaque fibroblasts were isolated from whole skin biopsies (Yerkes National Primate Cen-

ter, Atlanta, GA). The majority of skin was obtained from the back of female macaques that were euthanized for other purposes and tissues were kindly provided through the tissue sharing program by the
PI using the macaque for biomedical research. Foreskin was also obtained from male macaques, but the
tissue was difficult to use due to contamination. The macaques were negative for SIV and B virus antibody.
Whole skin biopsies were placed in PBS and stored at 4C until cells could be isolated (no more
than 24 h). The tissue was shaved to remove hair and cut into small pieces with a sterile scalpel.
Throughout the process the tissue was periodically rinsed in PBS containing penicillin, streptomycin with
anti-mycotic. The tissue was place in 0.4% Trypsin/EDTA (Mediatech, Manassas, VA) for 30 min at 37C
with vortexing intermittently. The tissue was further cut into smaller pieces and fresh trypsin was added
and kept overnight at 4C. The following day the tissue was resuspended with vortexing and pipetting
through a 25 ml down to a 10 ml. Once the majority of the tissue was disassociated, the cells were filtered using microfilters of 100 nm. The Rhesus Macaque Fibroblasts (RMF) were pelleted at 800 rpm
and resuspended in DMEM with 20% FBS and 1% antibiotic/antimycotic. Depending on the cell num-
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bers, RMFs were seeded into multi-well plates or a T25 flask. RMFs were cultured until they adhered (34 days) with intermittent addition of fresh medium. These were cultured until confluent and transferred
to the next largest growth flask at a 1:2 split ratio. This was considered passage (P) two. RMFs were
grown until a consistent split at a ratio of 1:2 was confluent in two days, which varied for each animal,
but was achieved by approximately P5. RMFs were used immediately or frozen in 10% DMSO with culture medium and stored in liquid nitrogen. For thawing of RMFs, tubes were placed in 37C for rapid
thaw and transferred to warm medium in a multi-well plate or T-25 at a high seeding density. RMFs
were cultured for one to two passages before using for experiments. RMF purity and isolation was verified using immunofluorescence with fibroblasts markers vimentin and fibronectin and cytokeratin, a
marker for keratinocyte contamination. Cells were fixed with methanol for 15 min, and blocked with
normal goat serum. These were subsequently labeled with the primary antibodies followed by goat antirabbit or mouse IgG (Sigma Aldrich, St. Louis, MO)-conjugated to the specific fluorophores, followed by
nuclear staining with Hoescht (Invitrogen, Grand Island, NY). Cells were visualized on a Zeiss AxioVert
200 (Zeiss, Thornwood, NY) (Figure 31).
2.4

B Virus Kinetics in Fibroblasts

B virus titers were determined in human foreskin fibroblasts and RMFs. Fibroblasts were grown
to confluency in 12-well plates. Fibroblasts were infected (MOI 5) for 1 h at 37C, 5% CO2. Samples were
collected at 1, 4, and 24h after infection by scraping and placed into a 1.5 ml microcentrifuge tube and
stored at -80C. Virus was quantified using a standard plaque assay (Figure 32). Additionally, to determine the amount of virus that remains cells associated, virus titers (infectious virions) were determined
for cells and supernatants (sup+cells) and supernatants only (sup) by standard plaque assay (Figure 22).
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2.5

Human and Macaque PBMC Isolation
Whole blood was collected from multiple healthy volunteers by veinipuncture into Becton Dick-

inson (BD) Vacutainer tubes containing sodium heparin (BD, Franklin Lakes, NJ). Blood was collected
with informed consent and with an approved IRB in accordance with federal and institutional policies.
Peripheral blood mononuclear cells (PBMC) were isolated by Lymphoprep (Axis-Shield, Oslo, Norway)
density centrifugation. Macaque blood was obtained from Yerkes National Primate Research Center
(Grant No. RR000165) and was collected in Becton Dickinson (BD) Vacutainer tubes containing sodium
heparin (BD, Franklin Lakes, NJ) from animals of varying ages prior to necropsy in accordance with
Yerkes National Primate Research Center’s IACUC requirements. PBMCs were used immediately or frozen in fetal bovine serum (FBS) with 10% dimethyl sulfoxide (DMSO) in cryo-containers at -80C and
stored in liquid nitrogen.
2.6

Plasmacytoid Dendritic Cell Isolation
Plasmacytoid dendritic cells were isolated from PBMCs by negative selection using the Human

Plasmacytoid Dendritic Cell Enrichment Kit (Stem Cell Technologies, Vancouver, BC). Briefly, unwanted
cells were labeled with tetrameric antibody complexes that recognize all non-pDCs and were selected
for using dextran-coated magnetic particles. The purity of isolated pDC was assessed by flow cytometry
using antibodies against BDCA-2 (CD303; Miltenyi Biotec, Auburn, CA) and BDCA-4 (CD304; Miltenyi Biotech, Auburn, CA).
2.7

Western Blot Analysis
Western blot was used to analyze protein expression in cell lysates. Briefly, cells were treated ac-

cording to the experiment and cells were lysed using Laemmli buffer (Biorad, Hercules, CA) containing mercaptoethanol. The collection volume depended on the experiment, but ranged from 50 l for small
plates up to 500 l for T25. Cell lysates were boiled at 99C for 5 min, placed on ice to cool, and then
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used immediately or stored at -80C. For most samples, a 7.5% SDS-polyacrylamide gel was assembled
and a 5% stacking gel. Samples were loaded in 10 l volume and a standard marker was used. Gels were
electrophoresed in running buffer for approximately two hours at 70V. Gels were transferred subsequently onto 0.45um nitrocellulose membranes (GE Healthcare Lifesciences, Piscataway, NJ) in transfer
buffer either overnight at 23 V or for 1 h at 70V. Protein transfer was verified using Ponceau S. Blots
were blocked in 5% blotto with non-fat dry milk for 1 h at room temperature. Primary and secondary
antibodies were used according to the manufacturers instructions. Blots were visualized by addition of
ECL substrate solution (GE Healthcare Lifesciences, Piscataway, NJ) at 1:1 concentration for 5 min followed by exposing to film for varying times, and developed using a Kodak Series 2000A Processor (Ti-Ba,
Inc., Rochester, NY).
2.8

ELISA for Interferon-
Interferon- concentrations were determined using an ELISA kit for Interferon- (MabTech, Inc.,

Mariemont, OH) according to the manufacturer instructions. Briefly, a 96-well high binding EIA/RIA ELISA plate (Santa Cruz, Dallas, TX) was coated with Mt 1/3/5 antibodies at 4 ug/ml in 100 ul in phosphate
buffered saline (PBS; MediaTech, Manassas, VA) overnight at 4C. Primary antibodies were removed,
plates were washed and after blocking, standard dilutions of IFN- and the samples were loaded into
the wells and incubated for 2 h at room temperature. The secondary antibodies, Mt 2/4/6 were added
and incubated at room temperature for 1 h, followed by the addition of strepavidin and 3, 3’, 5, 5’tetramethylbenzidine substrate (TMB; Biolegend, San Diego, CA). The reaction was stopped with 2N
H2S04 and the sample absorbance was read at A450nm using a BioTek Powerwave HT (Winooski, VT). A
standard curve was generated using GraphPad PrismTM and the unknown sample concentrations were
determined.
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2.9

PBMC Response to B Virus
To determine how PBMCs responded to B virus, human PBMCs were isolated from whole blood.

In 96-well plates, 1x106 PBMCs/well were exposed to various MOIs of B virus and cultured for 18-24 h in
RPMI-1640 containing 10% FBS and 1% antibiotic. Cell-free supernatants were collected by centrifuging
PBMCs at 100xg for 10min. Supernatants were collected in 1% Tween/DOC and stored at -80C until use.
Additionally, PBMCs were exposed to B virus infected fibroblasts in co-cultures. Briefly, fibroblasts were
infected with B virus for 1 h, 37C, 5% CO2. PBMCs were added to the infected fibroblasts in equivalent
amounts and cultured for an additional 23 h. Cell free supernatants were collected by centrifuging at
100xg for 10 min in 1% Tween/DOC and stored at -80C until analyzed.
2.10 Luminex Assay
Supernatants from co-cultures of pDCs with infected HFFs and pDCs were used in a LiquipChip
apparatus (Qiagen, Valencia, CA) for the detection of cytokines and chemokines. The kit used for analysis was the MilliplexTM Map Kit Human Cytokine/Chemokine 26-Plex (EMD Millipore, Billerica, MA) which
detects eotaxin, G-CSF, GM-CSF, IFN-α2, IFN-γ, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1α, IL1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIP-1α, MIP-1β, TNF-α, and TNF-β from each well.
The samples were analyzed according to the manufacturers instructions. The principle of the kit is the
use of microspheres that contain a fluorescent dye. Based on different concentrations of these dyes the
machine can detect multiple analytes from the same well. These microspheres are coated with capture
antibodies specific for each cytokine and chemokine. A secondary biotinylated antibody is added to the
wells and streptavidin (SA)-PE is used as a reporter molecule. The machine collects the samples and analyzes each microsphere and quantifies the fluorescence for the identification of each analyte, followed
by a secondary laser excitation of PE for quantification of the analyte. Standard curves and unknown
concentrations were generated and interpolated using Milliplex Analyst software (EMD Millipore, Billerica, MA).
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2.11 B Virus Titer Reduction Assay
To determine if B virus was sensitive to the effects of IFN-, either from PBMCs, PBMC cocultures or from recombinant IFN-, we set up several experiments. First, we tested the sensitivity of B
virus titers on cultures with supernatants from B virus-exposed PBMCs. To test this, PBMCs were cultured in 96-well round-bottomed plates and exposed to B virus at an MOI 5 for 24 h. Cell-free supernatants were collected by centrifugation at 100xg for 10 min. Supernatants were then transferred to B virus infected fibroblasts at 1 hpi and cultured for 24 h. Well contents were scraped and stored at -80C
until titered by standard plaque assay.
Secondly, we determined if B virus replication was sensitive to IFN- from co-cultures with
PBMCs. To test this, fibroblasts were infected with B virus at an MOI 5 for 1 h, in 48-well plates, at which
time, PBMCs were added to infected fibroblasts and cultured for 23 h. The well contents were collected
by scraping and stored at -80C. Samples were titered by standard plaque assay.
Lastly, the sensitivity of B virus was examined when fibroblasts were pre-treated for 30 min with
Universal Type I IFN (PBL Interferon Source, Piscataway, NJ) at varying doses. Fibroblasts were infected
with B virus for 1 h at which time IFN was added back to the cells, and cultured for an additional 23 h.
Samples were collected by scraping and stored at -80C. Samples were titered by standard plaque assay.
2.12 Plasmacytoid Dendritic Cells Response to B virus
For determination of the cytokines and chemokines produced, plasmacytoid DCs were equally
distributed into a round-bottomed 96-well plates. Each treatment was added in 200 ul RPMI-1640 with
10% FBS and 1% penicillin/streptomycin. As negative controls, “untreated” consisted of medium only
and mock-infected cell lysate (MCL) was added in the equivalent amount as B virus. For a positive control HSV-1 was used at an equivalent MOI as B virus, or CpG 2216 was used at 5 g/ml or 10g/ml (Invivogen, San Diego, CA). Treatments were added and cells were cultured for 24 h at 37C, 5% CO2. Cellfree supernatants were collected by centrifugation for 10 min at 100xg. Supernatants were transferred
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to a clean tube containing 10% Tween/DOC for a final concentration of 1% and stored at -80C until
used. Similarly, cytokines and chemokines were measured from B virus infected HFFs co-cultured with
pDCs. Briefly, HFFs were infected with an MOI 5 of B virus for 6 h then pDCs were added, and cultured
for an additional 18 h. Cell-free supernatants were collected by centrifugation at 100xg in 1%
Tween/DOC and stored at -80C.
To determine if the dose of B virus affects the amount of IFN- produced, pDCs were cultured in
a 96-well round-bottomed plate and exposed to increasing MOIs of B virus for 24 h. As a positive control
for cell function, CpG 2216 was used at 5 g/ml (Invivogen, San Diego, CA). Cell-free supernatants were
collected by centrifugation at 100xg in 1% Tween/DOC, and stored at -80C until analyzed by ELISA.
2.13 B virus modulation of IFN signaling pathway
To determine if B virus modulates the IFN signaling pathway, fibroblasts were grown in T25
flasks, infected with an MOI 5 of B virus and cultured for 24h. Cell lysates were collected at 2, 4, 6, and
24 h in 500 ul Laemmli buffer, boiled for 5 min at 99C and stored at -80C until used. Samples were run
on a 7.5% polyacrylamide gel and transferred by electroblotting to a nitrocellulose membrane. Blots
were blocked and probed with an antibody against phosphorylated (Y701) STAT-1 (p-STAT-1; BD Transduction Laboratories, San Jose, CA) at 1:1000 and total-STAT-1 (BD Transduction Laboratories, San Jose,
CA) at 1:1000. As a loading control, blots were probed with anti-GAPDH (Cell Signaling, Danvers, MA) at
1:1000.
Secondly, to examine if B virus blocks the IFN signaling pathway, fibroblasts were infected with B
virus at an MOI 5 for 1 h, then treated with 50 U/ml of recombinant Type I IFN for 30 min. Cell lysates
were collected in 50 ul of Laemmli buffer, boiled at 99C for 5 min and stored at -80C until used. Samples were run on a 7.5% polyacrylamide gel and transferred to a nitrocellulose membrane, and probed
for p-STAT-1, total-STAT-1 and GAPDH, all at 1:1000.
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2.14 Plasmacytoid dendritic cells do not support B virus replication
B virus infection of plasmacytoid dendritic cells
Plasmacytoid dendritic cells were infected with B virus at 10 pfu/cell. Virus was allowed to adsorb for 1 h or left on the cells for 24 h in RPMI-1640 (Mediatech, Manassas, VA) supplemented with
10% FBS (Atlanta Biologicals, Norcross, GA) and penicillin-streptomycin (Mediatech, Manassas, VA). In
some cases, a 50 mM citrate wash was used to inactivate any remaining virus outside of the cells. The
infections of pDC were measured by standard plaque assay and quantitative PCR (see below).
PCR for B virus transcripts
Quantitative real-time PCR. DNA was isolated from B virus exposed pDCs using the Easy DNA Kit (Invitrogen, Grand Island, NY) according to the manufacturers instructions. Herpes B virus DNA copies were
quantified using the Topo-PC DNA vector (Invitrogen, Grand Island, NY) containing the B virus gene for
glycoprotein B (gB;Irina Patrusheva, Viral Immunology Center, Atlanta, GA). Targeted gB was amplified
using the following primers for B virus gB: Forward: 5’AGGTTGATGAACGTGCTGAC 3’Reverse:
5’CGGGCTACGTGTACTTTGAG 3’. The sequence of the gB specific internal probe containing FAM-TAMRA
was 5’ ACTCCCACCAGCTGGGTCGC 3’. The PCR was performed using an ABI Prism 7900HT (Applied Biosystems, Grand Island, NY). Amplification conditions were 40 cycles of: 50C for 2 min, 95C for 10 min,
95C for 15 sec and 60C for 1 min. Standard dilutions of the gB vector were generated and unknown
samples were interpolated from the standard curve.
Reverse transcriptase PCR. pDCs were exposed to B virus at 2 pfu/cell and cultured for 24 h at 37C, 5%
CO2. Total RNA was purified using the manufacturer’s protocol for the TRI reagent RT (Molecular Research Center, Cincinnati, OH). To ensure DNA and RNAase removal, a DNA-free protocol (Ambion,
Grand Island, NY) was implemented. For PCR of B virus transcripts the following primers (Sigma-Aldrich,
St. Louis, MO) were used:
ICP0: Forward: 5’-CTCGAGCGTGGTGGCCAT-3’ Reverse: 3’- GGGTCATCCAGAGGCCGT-5’;
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Thymidine kinase: Forward: 5’-TGGACCTGGCCATGCTGTC-3’ Reverse: 3’-CAGCAGGTCGAGCGTCCAC-5’;
Glycoprotein C: Forward: 5’-GGTGGAGCTGCAGTGGCTG-3’ Reverse: 3’-CACTCGAGCGCGGTGGTCA-5’ and
-actin: Forward: 5’-GCCATGTACGTTGCTATCCA-3’ Reverse: 3’-TGGATGCCACAGGACTCCAT-5’ with the
Superscript One Step RT-PCR system with Platinum Taq DNA Polymerase (Invitrogen, Grand Island, NY)
on a Gene Amp PCR System 9700 (Applied Biosystems, Invitrogen, Grand Island, NY) with the following
program: 1 cycle at 55C for 30 min for reverse transcription, followed by denaturation for 2 min at
94C, and amplification with 40 cycles of 15 sec at 94C, 30 sec at 60C and 1 min at 68C, followed by a
final extension step at 68C for 5 min and then held at 4C. The amplification products were separated
on a 1.2% agarose gel (BioRad, Hercules, CA) and visualized.
2.15 Statistical Analysis
Statistical significance was measured using GraphPad PrismTM (LaJolla, CA) using a two-tailed
paired student t-test, which compares the means between repeats of experiments containing one dependent variable and a minimum of two independent variables. The experiments measuring B virus titers in fibroblasts (Figures 18, 22 and 23) and in pDCs (Figure 20) were analyzed by Student’s t-test.
Analysis of variance (ANOVA) analyses were used to measure the significance of the results from
experiments with two or more independent variables (Figures 16, 17, 19, and 21). ANOVA analyses require at least 3 repeats and more than two independent variables. ANOVA compares the overall mean
across the independent variables while the application of a post-hoc test generates a p-value based on
the means between the groups. For all ANOVA analyses a post-hoc test of Newman-Keuls was applied,
which allows comparison of the mean of each independent variable with the controls, generating a pvalue for each independent variable. All significant values were p<0.0001 (***) or p<0.05(**). Values
that were not significant were designated with a NS.
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3

RESULTS AND DISCUSSION

Based on the characteristics of zoonotic B virus infection in humans, i.e., few-to-no adaptive defenses, we designed experiments to study deficiencies in innate immunity that may underlie the failure of
mounting effective adaptive defenses. We elected to study pDC responses to B virus because pDCs are the
primary source of abundant amounts of Type I interferons, the primary antiviral molecules in mammalian
species. There are no animal models that recapitulate infection in either macaque or humans therefore; we
designed a cell culture model system to better understand innate defenses following B virus infection. To
utilize this model, we first collected fresh, whole peripheral blood from multiple healthy humans and isolated PBMCs by density centrifugation. It is important to point out that B virus is not viremic (detected in
blood) and the additional of peripheral blood PBMCs was to mimic the infiltrating PBMCs from blood into
infected tissues. We then used a pDC isolation kit to purify pDCs from pooled PBMCs by negative selection,
which prevented receptor-mediated activation and led to a 97% enrichment of pDCs that were BDCA-2
(CD303) and BDCA-4 (CD304) positive (Figure 14). There are currently no available reagents for the isolation
of pDCs from macaques so we used human pDC and human/macaque PBMC responses following exposure
to B virus as a measure of species-specific IFN responses.
3.1

Human plasmacytoid dendritic cell response to B virus
Both natural and zoonotic B virus infections usually originate in the skin through a bite or a

scratch from an infected monkey or a splash with contaminated fluids into an open mucosal site (e.g.,
eye, mouth, etc.) or external wound. The virus replicates at the site of entry within keratinocytes and
fibroblasts, the first target cells infected. These infected cells, and possibly adjacent cells often send signals in the form of cytokines or chemokines to recruit nearby immune cells, such as plasmacytoid dendritic cells unless these host defenses are blocked by the virus. Plasmacytoid dendritic cells are important producers of Type I IFNs that engage innate defense activation and shape type of adaptive im-
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mune pathways engaged as a result of viral infections. Dendritic cells are central for the generation of an
immune response. A characteristic of zoonotic B virus infection, which is the induction of limited, early
and ineffective adaptive defenses, along with the knowledge of the roles of pDCs in antiviral immunity,
led us to formulate the hypothesis that B virus blocks the production of cytokines and chemokines from
human plasmacytoid dendritic cells (pDC). We tested our hypothesis in a human cell-culture model to
mimic natural infection (Figure 15). We quantified pDC cytokine and chemokine production following
pDC exposure to B virus infected cells through co-culture with these versus direct exposure to B virus
released from infected cell lysates. B virus replication in human fibroblasts results in the fusion of infected and healthy fibroblasts, syncytial formation, to ultimately limit the release of virions, potentially limiting the numbers of virions to which defense systems are exposed.
The pDCs were isolated by negative selection from PBMCs from healthy individuals who were
sero-negative to B virus, HSV-1 and 2, using the Human Plasmacytoid Dendritic Cell Isolation Kit (Stem
Cell Technologies, Vancouver, BC). The isolation yielded pDCs with a purity of approximately 98% as
measured by FACS screening for BDCA-2 and BDCA-4 positive cells (Figure 14). Due to the low concentration of pDCs in peripheral blood (0.1-0.8% of PBMCs) it was necessary to pool blood from multiple
donors. Although pDCs could be recruited to infected lesions from blood, our experimental setup utilized peripheral blood pDCs representative of infiltrating pDCs and we used pDCs numbers much higher
(103-104 pDCs/experiment) than would be observed in natural infection (~1-2 pDCs per lesion) because
the activity of pDCs in tissue would be below detection. We have previously shown that pDCs from different donors responded differently to synthetic DNA (CpG/ODN 2216) (Figure 30 in Appendix). To correct for differential responses between heterogeneous pDCs, we used two negative controls: (i) pDCs
exposed only to culture medium to determine any basal pDC responses and (ii) pDCs exposed to uninfected cell lysates, which were generated in the same way as B virus stocks, designated as mock cell lysate (MCL) and at least one positive control (i) HSV-1, endemic in humans, was used because it induces
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high amounts of IFN- from pDCs and is a closely related herpes virus to B virus, and/or (ii) CpG/ODN
2216, which is a synthetic DNA oligonucleotide that induces IFN- via TLR9.

Figure 14 Human pDC purity after isolation from PBMCs.
BDCA-2 and-4 were used as markers of pDCs within PBMCs (A) and after pDCs purification using the Stem Cell Human
pDC Isolation Kit (B), which resulted in a purity of approximately 98% (bottom right) by FACS analysis. PBMCs contain
approximately 1.5% pDCs prior to isolation. As a negative control, cells were left unlabeled (left squares) to rule out autofluorescence. Double-labeled pDCs are shown in the right column and are positive for BDCA-4 and BDCA-2.
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Figure 15 The experimental design to measure the pDC response to B virus

4

A. Illustrates the co-culture system of pDCs with B virus infected human foreskin fibroblasts (HFFs). HFFs (2x10 ) were exposed
to two negative control groups (1) Medium and (2) MCL. For the test group, HFFs were infected with (3) B virus (MOI 5) and for
a positive control (4) HSV-1 (MOI 5). All treatements were kept on HFFs for 1h, at which time the treatments were removed and
4
fresh culture medium added. At 6hpi, 1x10 ppDCs were added to treated HFFs and cultured an additional 18h. Supernatants
were collected and analyzed for 26 different cytokines and chemokines.
4
B. 1x10 pDCs were exposed to one of four treatments to determine how pDCs respond when directly exposed to B virus cell
lysates. As negative controls, pDCs were exposed only to (1) culture medium and or to (2) MCL (mock cell lysate) which was
added at the equivalent amount as for the B virus treated group. The test group consisted of pDCs exposed to (3) B virus (MOI
5) and as a positive control pDCs were exposed to (4) HSV-1 (MOI 5).

Our first goal was to test the hypothesis that pDCs would not produce cytokines or chemokines
after exposure to B virus via infected human foreskin fibroblasts (HFFs). Our goal was to measure the
response of pDCs exposed to B virus infected HFFs. A pictorial of this experiment is presented in Figure
15A. To verify that pDCs were capable of producing cytokines and chemokines, we cultured pDCs directly with B virus released from infected cell lysates and the controls as depicted in Figure 15 B. Human
foreskin fibroblasts (HFFs) were grown to near confluency (2x104 HFFs/well) in a 96-well plate and exposed to one of the four different treatments: (1) culture medium only, (2) MCL, (3) B virus (MOI 5), and
HSV-1 (MOI 5). To evaluate that a measureable response was due to B virus, we used two negative controls, medium and MCL, present in the same amounts found in B virus lysates. HSV-1 was the positive
control because it is a closely related herpes virus endemic in humans and is known to induce robust
amounts of IFN- from pDCs, as previously discussed. Virus was adsorbed to cells in minimal amounts of
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medium for 1 h at 37C. Unadsorbed virus, medium, and MCL were removed from each of the respective wells in this experiment and replaced with pDC culture medium (RPMI-1640 supplemented with
10% FBS and 1% antibiotic). The HFFs were cultured for a total of 5 h after adsorption to allow B virus to
progress through the virus replication cycle. By this time, immediate-early, early, and some late genes
have been expressed. At 6 hpi, the culture medium was removed and 1x104 freshly enriched pDCs were
added in fresh medium and this co-culture was incubated for an additional 18 h. In parallel, the aliquots
of this pool of pDCs were seeded into separate 96-well plates to measure their response to B virus released into infected cell lysates. Controls were also exposed to the same control treatments used for the
parallel experiment. The supernatants were collected 18h after the addition of pDCs and clarified by
centrifugation at 100xg for 10 min. Each supernatant contained tween/DOC, at a final concentration of
1% each to ensure that any B virus present was inactivated prior to removal from the BSL-4, in accordance with the CDC’s BMBL guidelines (5th Ed.) The supernatants were removed from the BSL-4 and
stored at -80C.
To maximize the amount of data collected from these samples, a multiplex assay was used to
measure the pDC response to (1) B virus infected HFF in co-cultures and (2) B virus released into infected
lysates. The MilliplexTM Map Kit Human Cytokine/Chemokine was purchased from Millipore to quantifies the levels of 26 cytokines and chemokines within each collected sample, viz., eotaxin, G-CSF, GMCSF, IFN-α2, IFN-γ, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-7, IL-8, IP-10, MCP-1, MIP-1α, MIP-1β, TNF-α, and TNF-β. The principle of the kit is the use of microspheres that contain a fluorescent dye. Based on different concentrations of these dyes the Luminex
machine can detect and differentiate multiple analytes from the same well. These microspheres are
coated with capture antibodies specific for each cytokine and chemokine. A secondary biotinylated antibody is added to the wells and streptavidin (SA)- phycoerythrin (PE) is used as a reporter molecule. The
machine collects the samples and analyzes each microsphere and quantifies the fluorescence for the
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identification of each analyte, followed by a secondary laser excitation of PE for quantification of the
analyte. The software supplied by Millipore was used to determine the concentration of each analyte
based on a standard curve generated from known standards. As shown in Figure 16, pDCs co-cultured
with B virus infected HFFs (white bars), produced significant amounts of IFN- and TNF-, but none of
the other cytokines measured. In contrast, pDCs exposed to B virus released into infected cell lysates
(gray bars) produced significant amounts of IL-1 IFN-IL-6, and TNF-possibly as a result of exposure to unpackaged viral DNA also released into lysates. Similarly and as shown in Figure 17, pDCs cocultured with B virus infected HFFs produced significant levels of IP-10, whereas, pDCs directly exposed
to B virus infected cell lysates responded with significant production of IL-8, MIP-1, MIP-1 and IP-10.
The raw values for the cytokines and chemokines are presented for inspection in Tables 4 and 5 located
in the Appendix. To better understand the impact of pDCs exposed during in zoonotic infection, it is important to consider the functions of the pDC produced cytokines and chemokines in relation to the recruited immune cells and the potential consequences.
IL-1is also known as fibroblast-activating factor and B cell-activating factor. It is constitutively
produced by epithelial cells, and can be induced in a number of cells, including fibroblasts, macrophages,
granulocytes and dendritic cells, just to name a few. IL-1 has been shown to activate keratinocytes and
macrophages to induce more IL-1, but also can enhance the proliferation of fibroblasts, CD4+T cells,
induce the production of IL-2 and IL-6, activate CD8+ T cells, induce the proliferation of mature B cells
and induce Ig production in the presence of mitogens. As shown in the top panel of Figure 17, pDCs cocultured with B virus infected fibroblasts failed to induce any significant amount of IL-1 (1.75 pg/ml),
while direct exposure to B virus and the contents of lysed infected cells induced ~100pg/ml of IL-1,
which was significant by ANOVA with a post-hoc analysis of Newman-Keuls. Our positive control, HSV-1
infected cells co-cultured with pDCs failed to result in the production of significant levels of IL-1,
whereas exposure of pDCs to HSV-1 released into infected cell lysates induced 2.5 times greater levels of
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IL-1 than pDCs directly exposed to B virus released into infected cell lysates. Each of the negative controls of medium and MCL failed to induce any IL-1 from pDCs exposed to lysed cells or co-cultured with
HFFs, underscoring that the response was specific to virus and not cells, intact or lysed. These data suggest that B virus presented within the context of the co-culture experiments does not induce measureable IL-1 production from pDCs. IL-1 production during zoonotic infection could support multiple aspects of the immune response to B virus by activating and inducing the proliferation of T cells and B
cells, neither events observed in B virus infected humans. The lack of production of IL-1 from pDCs in
response to B virus infected HFFs implies that pDCs would fail to activate T and B cells or support the
healing of skin at the site of infection. The positive control, HSV-1 infected fibroblasts, also failed to induce any IL-1 from pDCs, indicating that IL-1 may not be an important player in simplex virus infections.
The presence of IFN- can influence both innate and adaptive immune cells, including NK cells, B
cells, T cells, monocytes and dendritic cells, but can also affect primary cells, such as fibroblasts that are
permissive to infection by B virus. IFN- can turn on various and multiple anti-viral IFN-dependent gene
pathways such as RIG-I, and MDA-5, NF-B, and induce the expression of interferon-stimulated genes
(ISGs). pDCs provide a major source of IFN- in the context of herpes virus infections. As shown in the
second panel of Figure 16, B virus infected HFFs co-cultured with pDCs (white bars) produced significant
levels of IFN- at 300pg/ml, while pDCs exposed to B virus release in infected cell lysates (gray bars)
produced 2500 pg/ml of IFN-, 8 times more than in co-cultures. In data not shown, HFFs alone failed to
induce any IFN- after B virus infection (N. Brock, 2013 and M. Vasireddi, 2009), underscoring that pDCs
are a source of IFN-. Our negative controls of medium and MCL, failed to induce significant amounts of
IFN- (4 pg/ml and (14.23 pg/ml), respectively) from co-cultures of HFFs with pDCs, indicating that the
observed responses were not attributable to cells or cellular organelles. Our positive control of HSV-1
infected HFFs co-cultured with pDCs (white bars) resulted in the production of 450 pg/ml of IFN- while
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pDCs exposed to HSV-1 released into infected cell lysates (gray bars) produced 5000 pg/ml of IFN- from
pDCs, both levels which were significant relative to levels produced as a result of just co-culture or lysed
cells when using ANOVA. The impact of IFN- produced from pDCs was explored in this dissertation in
the context of Type I IFN signaling pathway activation and will be discussed later (Figures 25-28) and the
effects of IFN- on the extent of B virus replication in fibroblasts (Figures 23 and 24). The extent of the
reach and activity of the secreted IFN- needs further investigation in the context of immune cell activation.
IL-6 is a cytokine known to induce B cell differentiation into plasma cells, supports T cell growth
and differentiation, induces the development of macrophages, activates keratinocytes and mediates
lymphocyte trafficking. As shown in the third panel of Figure 16, IL-6 (400 pg/ml) was produced by pDCs
co-cultured with HFFs exposed only to medium while MCL infected HFFs co-cultured with pDCs resulted
in the production of twice these levels (800 pg/ml). Co-cultures of B virus or HSV-1 infected HFFs with
pDCs, designed to reflect infected skin cells in vivo in the presence of pDCs in the vicinity, produced lower levels of IL-6 (100 pg/ml) when compared to the negative controls. The ability of pDCs to respond was
verified by exposing pDCs to lysed infected cells, which resulted in production of 50 pg/ml of IL-6. Our
co-cultures of B virus infected HFFs and pDCs induced twice as much IL-6 than pDCs directly exposed to
virus in infected lysates, most likely because both pDCs and HFFs can respond to direct B virus exposure
with the production of IL-6. Interestingly, HFFs treated with MCL produced 4500 pg/ml (M. Vasireddi,
2009), while MCL treated HFFs co-cultured with pDCs produced less IL-6 at 800 pg/ml, suggesting that
HFF co-culture with pDCs may limiting the IL-6 production by HFFs or that nucleic acids released from
lysed cell may be an important stimulant for activation of pDCs. Over-production of IL-6 can be detrimental to a host, so it is likely that pDCs or other cell types may regulate excessive production of IL-6.
The suppression of IL-6 by B virus, relative to MCL, suggests either a direct or indirect virus-specific block
or modulation of IL-6, which would benefit B virus survival and promote virus spread. The importance of
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IL-6 in protection against zoonotic B virus infection is likely minimal as our positive control of HSV-1, an
endemic human herpes virus that is rarely fatal, also suppressed IL-6 production when infected HFFs
were co-cultured with pDCs. While the impact of IL-6 during B virus infection was not explored, pDCs can
contribute to immune responses against B virus by activating skin cells, recruiting and activating macrophages, driving TH2 immune responses against B virus by promoting B cells differentiation. pDCs exposed to HSV-1 infected cell lysates produced IL-6 to a greater degree (5-fold) than pDCs exposure to B
virus infected cell lysates. IL-6 has been shown by other investigators to be critical for resistance to HSV1 in selected mouse strains [210]. Although the levels of IL-6 produced during virus infected co-cultures
were similar between B virus and HSV-1, the role of IL-6 in zoonotic B virus infection remains to be investigated.
TNF- (tumor necrosis factor or TNF), also produced by pDCs, is a highly inflammatory cytokine
involved in the activation of many signaling pathways within both immune and non-immune cells. It is
produced by many cell types including CD4+ T cells, NK cells, DCs, fibroblasts and endothelial cells and is
a potent chemoattractant for neutrophils. TNF- induces the production of cytokines and chemokines
from many cells, stimulates phagocytosis in macrophages, activates apoptosis pathways, and is the key
mediator of sepsis. TNF-has been shown to be essential in preventing herpes simplex encephalitis in
mice [152]. There are no data available on the production or impact of TNF- during zoonotic B virus
infection. As shown in the bottom panel of Figure 16, pDCs responded to the presence of B virus infected fibroblasts by producing significant amounts of TNF- at 75 pg/ml (white bars). Our positive control
of HSV-1 infected HFFs co-cultured with pDCs produced 187 pg/ml of TNF. Direct exposure of pDCs with
B virus infected cell lysates, however, induced 406 pg/ml of TNF, indicating that pDCs were capable of
producing greater levels when compared to those observed from co-cultures. The positive control of
HSV-1 infected cell lysates induced 786 pg/ml, almost 2 times as much as pDCs directly exposed to B virus infected cell lysates. Our negative controls of medium (0.43 pg/ml) and MCL (0.58 pg/ml) did not
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induce significant amounts of TNF- in co-cultures of pDCs with HFFs, confirming that the response was
specific to virus. In data not shown, B virus infection of HFFs alone failed to produce any TNF-, confirming that production was from pDCs (M. Vasireddi, 2009). These results suggest that pDCs in the presence
of zoonotically infected cells are a source of TNF-, which would recruit and activate neutrophils, trigger
phagocytosis of macrophages and induce apoptosis of infected cells. Future studies in more complex cell
co-culture models are planned for the future, and these may lead to the development of an effective
small animal model.
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Figure 16 Cytokines produced from B virus-exposed pDCs
Human pDCs were isolated by negative selection from pooled PBMCs from several antibody-negative donors and
exposed to B virus infected cell lysates or to B virus infected HFFs. pDCs produced significant levels (P<0.0001) of
IL-1, IFN-, IL-6 and TNF- in response to direct exposure to B virus infected lysates (gray bars), but pDCs produced significant levels (p<0.05) of only IFN- and TNF- in the presence of intact B virus infected HFFs (white
bars). There was a significant (p<0.05) down-regulation of IL-6 from pDCs exposed to B virus infected HFFs when
compared to MCL treated HFFs. Statistical analysis was performed on data from triplicate samples from one experiment using ANOVA with a post-hoc of Newman-Keuls **p<0.05 ***p<0.0001. Error bars represent mean of the standard error (SEM). The table shows the mean value of each cytokine and the ratio of the mean of pDC cytokine production when directly exposed to B virus lysates divided by the mean of pDC cytokine production in response to infected
HFFs. ND=not detected, NA=not applicable.

Many cells produce chemotactic cytokines or chemokines as a form of communication, and for
the recruitment of effector immune cells. pDCs are one of the first responders to invading viruses, so
any chemokines produced by pDCs will help shape the immune response by directing the recruitment of
effector cells. Therefore, we designed an experiment to measure chemokines produced by pDCs in re-
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sponse to intact B virus infected HFFs or to direct exposure to B virus infected cell lysates. We tested the
same supernatants that we obtained for the cytokine analysis described above and had the same negative controls of medium and MCL to verify the chemokines were specific to B virus, and HSV-1 was again
used as a positive control. The data revealed for the first time that B virus infected HFFs fail to induce
any significant amounts of the chemokines measured, except for IP-10. The pDCs were functional as direct exposure to B virus infected cell lysates induced significant amounts of IL-8 (CXCL8), MIP-1 (CCL3),
MIP-1(CCL4), and IP-10 (CXCL10). The lack of chemokine production by pDCs exposed to B virus infected HFFs provides a major roadblock, which can prevent the development of an efficient and effective
immune responses, which is lacking in the fatal cases of zoonotic B virus infection. What is lost in the
absence of each of these chemokines? To better understand, we summarize what each of these normally function to recruit.
IL-8 or CXCL8 is a chemokine produced by mononcytes, macrophages, fibroblasts, endothelial
cells, dendritic cells and keratinocytes, and can be induced by IL-1 and TNF-. IL-8 is a chemotactic protein that can recruit all migratory immune cells. It can activate neutrophils for the release of cytotoxic
granules and can also influence the production of immunoglobulins from B cells. As shown in Figure 17,
pDCs respond to B virus infected HFFs with 87 pg/ml of IL-8 production, and our positive control of HSV1 infected HFFs produced 89 pg/ml, but the levels were significantly less than those measured in to the
negative controls of medium (1500 pg/ml) and MCL (2500 pg/ml) co-cultures. In contrast, direct exposure of pDCs with B virus infected cell lysates produced 400 pg/ml of IL-8 and HSV-1 infected cell lysates
induced 750 pg/ml of IL-8, which was nearly twice the levels produced by B virus exposed pDCs. These
responses were specific to virus as both of the negative controls for direct exposure failed to induce any
IL-8. The role of IL-8 in neutrophil activation is well known. Neutrophils play a major role in the early response to HSV-1 infection. While there are many cells capable of producing IL-8, it is important to note
that pDCs contribute to neutrophil recruitment and activation. Previous work in our lab has shown that
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B virus infected HFFs fail to recruit neutrophils in experiments with transwell co-cultures, whereas HSV-1
infected HFFs are able to recruit neutrophils under similar conditions. These results only tested the effect of one cell type, HFFs, so the data presented here suggest a more telling possibility of limited immunity, also observed in fatal zoonotic infections. The failure of pDCs to produce key recruiting chemokines such as IL-8 in co-cultures with infected HFFs is likely a critical step in developing immunity against
this fatal virus and may be a target for therapeutic modulation.
MIP-1 or (CCL3) and the closely related MIP-1 (CCL4) are chemokines involved in the recruitment of immune cells such as T and B cells. They are produced by a number of cells, including macrophages, CD8+ T cells, B cells, neutrophils, dendritic cells, natural killer cell, keratinocytes, fibroblasts and
many more. They are involved in recruitment of innate immune cells, in development of a TH1 response
and in CD4+ T cell differentiation. They can also induce cytokine production from fibroblasts, specifically
IL-1, TNF- and IL-6. As shown in the second and third panels of Figure 17, pDCs in co-culture with B virus infected fibroblasts (white bars) failed to produce any significant levels of MIP-1 or MIP-1 at
0pg/ml and 4pg/ml, respectively. Similarly, neither negative control induced pDC production of significant amounts of MIP-1 or MIP-1. Our positive control, pDCs co-cultured with HSV-1 infected fibroblasts also failed to induce MIP-1, but induced 55pg/ml of MIP-1. We know that the pDCs were functional because direct exposure (gray bar) with B virus infected cell lysates resulted in the production of
150 pg/ml of MIP-1 and 190 pg/ml of MIP-1from pDCs, and our positive control, direct exposure of
pDCs to HSV-1 infected cell lysates, resulted in the production of 600 pg/ml of MIP-1 and MIP-1.
These data indicate that pDCs in co-culture with B virus infected HFFs would not be able to recruit many
different types of immune cells. Whether the levels of MIP-1 and MIP-1 produced from B virus exposed pDCs are sufficient for the recruitment of immune cells requires additional experiments.
IP-10 (CXCL10) also known as interferon gamma-inducible protein 10 is produced by a number of
cells such as keratinocytes, lymphocytes, monocytes, dendritic cells and macrophages. Production of IP-

56
10 can be induced by IFN- or TNF- and is a potent chemoattractant for monocytes, macrophages, T
cells and DCs. Of the chemokines measured and as shown in the bottom panel of Figure 17, IP-10 was
the only chemokine produced in significant levels (275 pg/ml) when pDCs were co-cultured with B virus
infected HFFs. Our positive control, HSV-1 infected HFFs co-cultured with pDCs induced 300 pg/ml of IP10, which was nearly equivalent to pDCs co-cultured with B virus infected HFFs. Our negative controls,
pDCs co-cultured with HFFs exposed to medium or MCL also induced IP-10, but in significantly lower
levels at 5 pg/ml and 91 pg/ml, respectively. HFFs exposed to MCL induced half as much of IP-10 than
with MCL treated HFFs co-cultured with pDCs (data not shown; M. Vasireddi, 2009). pDCs directly exposed to B virus infected cell lysates produced robust amounts of IP-10 at 2500 pg/ml, 10 times as much
as co-cultured pDCs, verifying that pDCs were functional. Our positive control, pDCs directly exposed to
HSV-1 infected cell lysates produced 4000 pg/ml of IP-10, about 1.5 times more than pDCs directly exposed to B virus infected cell lysates. This response was specific to B virus as both of the negative controls of medium and MCL failed result in the production of induce IP-10 from directly exposed pDCs. The
production of IP-10 was likely induced by TNF-, as both B virus and HSV-1 exposed pDCs produced high
amounts of TNF- (406 pg/ml and 786 pg/ml, respectively), but failed to produce any detectable levels
of IFN-. IP-10 is a potent recruiter of many innate immune cells and production by pDCs co-cultured
with B virus infected HFFs would allow for recruitment and the development of an antiviral immune response against B virus, but whether these levels are sufficient requires further experiments.
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Figure 17 Chemokines produced from B virus-exposed pDCs
Human pDCs were isolated by negative selection from pooled PBMCs from antibody negative donors and
exposed to B virus infected cell lysates or to B virus infected HFFs. pDCs induced significant levels
(P<0.0001) of IL-8, MIP-1, MIP-1 and IP-10 in response to direct exposure to B virus infected lysates
(gray bars), but pDCs only induced significant levels (p<0.05) of IP-10 in response to B virus infected HFFs
(white bars). Statistics were triplicate of one experiment using ANOVA with a post-hoc of Newman-Keuls
**p<0.05 ***p<0.0001. Error bars represent mean of the standard error (SEM). The table shows the mean of
each chemokine and the ratio of the mean of pDC chemokine production when directly exposed to B virus
lysates divided by the mean of pDC chemokine production in response to infected HFFs. ND=not detected,
NA=not applicable.
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3.2

HFFs in pDC co-cultures produce infectious B virus
In an effort to explain why pDCs co-cultured with B virus infected HFFs produced fewer and lower

concentrations of the cytokines and chemokines than pDCs directly exposed to B virus infected cell lysates, we hypothesized that the amount of virus available to pDCs in the context of B virus infected HFF
co-cultures was significantly less than that in direct exposure to B virus cell lysates. B virus virions are
primarily cell-associated, as observed by the ability of B virus to form syncytia in multiple cell types, including Vero cells (Figure 5), HFFs, and rhesus macaque fibroblasts (RMFs). The fusion of infected cells
with healthy cells is one virus strategy that helps to limit the numbers of free virions (not cell-associated)
available for immune surveillance, but still allows virus to enter peripheral neurons, wither by fusion of
infected cells with neuronal membranes or escape of enveloped virions. To test this, we grew HFFs to
subconfluency in a 12-well plate and infected them with B virus (MOI 5). Unadsorbed virus was removed
after 1h and fresh culture medium was added and cultured these for an additional 23h. To quantify the
amount of virus released from these infected cells we collected only the supernatants from infected
HFFs after 24 h of infection (SUP). In addition, we collected both the HFFs and supernatants to quantify
the amount of virus that is cell-associated and released into the supernatants (SUP+CELLS) from B virus
infected HFFs after 24h of infection. We used a standard plaque assay to quantify the amount of virus
within each sample, which is done by creating serial dilutions of the unknown samples, adding a known
volume of each dilution onto confluent Vero cells, overlaying with methylcellulose and culturing for 48h.
Plaques appear as spaces due to cell death and represent individual infectious virions, which after staining with crystal violet are counted and virus titers are determined. The results were calculated and expressed as the titers for 2x104 HFFs, the same amount of HFFs that were infected in the co-culture studies. As shown in Figure 18, B virus titers in the supernatants only (HFF sup) were 1.8x104 pfu, which was
significantly less (p<0.05) by student t-test than the nearly 10-fold greater titer of HFF and supernatants
(HFF sup+cells) at 1.3x105 pfu. Based on these data, the amount of virus available to pDCs in co-cultures
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with infected HFFs was less nearly 4-fold less than that amount of B virus released from lysed infected
cells for exposure to pDCs in direct exposure or 5x104 pfu (represented by the dashed line in Figure 18).
This reduction in virus levels correlated with significantly reduced levels of cytokines and chemokines
produced by pDCs in co-cultures with infected HFFs.

Figure 18 B virus titers in human fibroblasts
HFFs were infected at an MOI of 10 in 12-well plates. After 24h, B virus titers in cell-free medium were measured by
standard plaque assay to determine the amount of cell-free virus available to pDCs in the co-culture experiment de4
5
4
scribed above. HFF sup resulted in 1.8x10 pfu and HFFs sups+cells resulted in 1.3x10 pfu per 2x10 HFFs. The dashed
4
line represents the titer of B virus that pDCs were exposed to B virus infected cell lysates (5x10 pfu). HFF=human
foreskin fibroblasts, sup=supernatant, sup+cells= supernatant and infected cells. Error bars represent SEM of triplicate samples. **p<0.05 using student’s t-test for comparison of the means values.

3.3

IFN- from pDCs is dependent on B virus dose
To extend our experiments from looking at the amounts of B virus produced from HFFs during

co-culture, we wanted to determine how different doses of B virus infected cell lysates would affect IFN production from pDCs. We chose IFN- as the measure of the pDC response to B virus infected cell
lysates because pDCs are the most potent producers of Type I IFNs in response to viral nucleic acids. Our
previous experiment showed that the titers pDCs were exposed to in co-culture with B virus infected
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HFFs were about 4 times lower than the titers of B virus released from infected cell lysates. Based on
these data we hypothesized that pDC-induced IFN- correlated directly with virus dose to which these
were exposed. To determine the effect of virus dose on the ability of pDCs to produce IFN-, freshly isolated pDCs from pooled PBMCs collected from seronegative donors were exposed to B virus at 2, 5, 10
and 20 pfu/cell. To ensure that the pDCs were responsive to B virus two positive controls were used, ie.,
HSV-1 at 5 pfu/cell and CpG 2216 at 5g/ml. The pDCs were seeded in 50ul of culture medium into 96well round-bottomed plates and each treatment was added in 150ul of culture medium. pDCs were cultured at 37C, in a 5% CO2 humidified incubator, and at 24h cell-free supernatants were centrifuged at
100xg for 10min to remove cells and debris and tween/DOC was added to a final concentration of 1% to
inactivate virus. Supernatants were stored at -80C until analyzed by ELISA for IFN- using the Human
IFN- pan ELISA Development Kit (HRP) (MabTech, Cincinnati, OH). This kit detects 11 of the 12 subtypes
of IFN- using a sandwich ELISA technique with a capture antibody and a detection antibody conjugated
with horseradish peroxidase (HRP). Serial dilutions of a standard provided with the kit allowed for generation of a standard curve and unknown IFN- concentrations were interpolated using RIA
Spline/LOWESS in GraphPad PrismTM. As shown in Figure 19, the pDCs responded to B virus released
from the infected cells during the course of infection with the production of IFN- although it was inversely correlated to the dose of B virus. Both of our positive controls verified that the pDCs were responsive by producing IFN- in response to HSV-1 infected cell lysates and CpG 2216 with 33 fg/cell and
42 fg/cell, respectively. The pDCs exposed to B virus released from infected cell lysates at 2 pfu/cell (or
2x104 pfu) produced 33.5 fg/cell of IFN-, while pDCs exposed to B virus released from infected cell lysates at 5 pfu/cell (6x104 pfu) produced 28 fg/cell of IFN-, while high MOIs of B virus released from infected cell lysates at 10 pfu/cell (1.2x105 pfu) and 20 pfu/cell (2.4x105 pfu) failed to induce significant
amounts of IFN- at 4 and 5 fg/cell, respectively. Neither of the two negative controls, cells exposed to
medium or MCL (at the protein equivalent to BV 20 pfu/cell), produced any IFN-, indicating that the
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IFN- produced was a specific response to virus. This result was unexpected because independent studies with HSV-1 have shown that the more virus, the greater the amount of IFN- pDCs produce, indicating that high MOIs of B virus may high MOIs of block or overwhelm pDC IFN- production. These data
support our hypothesis that IFN- production by B virus exposed pDCs correlates inversely with the
amount of virus used to expose pDCs, surprisingly. Based on these data and the data shown in Figure 18,
the pDCs in co-cultures with B virus infected HFFs (1.8x104 pfu) should produce similar amounts of IFN-
as pDCs in direct exposure to B virus infected cell lysates (5x104 pfu) as there was no significant difference of IFN- produced from pDCs exposed to 2 or 5 pfu of B virus, both of which had significantly higher production of IFN- than pDCs exposed to MCL (Figure 19). To explain the drastic reduction of IFN-
production from pDCs in co-cultures when compared to pDCs directly exposed to B virus infected cell
lysates, we considered the quality of virus within the virus lysates as these virions are likely surrounded
by the nuclear or Golgi membranes whereas the virions released from infected cells in co-cultures would
be surrounded by plasma membranes acquired when virions egress out of infected cells by exocytosis.
Another possible explanation for the increase of IFN- in pDCs directly exposed to B virus infected cell
lysates is that these contain free viral DNA that is available for the pDCs to endocytose and activate TLR9
dependent IFN- production. There is likely to be very little free DNA in the co-culture system, as only
intact virions would be released with the DNA protected within the enveloped capsid. Future studies
are needed to fully understand the mechanism of a differential response between B virus infected cell
lysates and the B virus virions produced from infected HFFs in co-cultures.
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Figure 19 IFN- production from pDCs is inversely correlated to virus within infected cell lysates
pDCs were isolated by negative selection from pooled, fresh PBMCs obtained from seronegative donors and were distributed equally into wells of a 96-well plate. pDCs were exposed to B virus in infected cell lysates with titers ranging from 220 pfu/ml, as determined by standard plaque assay. pDCs were cultured for 24h and cell-free supernatants were collected
and tween/DOC, added to a final concentration of 1%. IFN- levels were determined using ELISA. As negative controls,
medium treated pDCs and MCL treated pDCs, at a level equivalent to BV 20 pfu, were used. As positive controls, pDCs
were exposed to HSV-1 at 5 pfu/cell and pDCs were exposed to 10ug/ml of CpG 2216. **p<0.05, NS=not significant.
ANOVA was used to analyze results along with Newman-Keuls post hoc test for pair comparisons.

3.4

pDCs do not support productive B virus replication
We showed that pDCs exposed to high titers (>10 pfu/ml) of B virus fail to produce significant

amounts of IFN-(Figure 19). The viability of pDCs after B virus exposure was unchanged for all titers
(data not shown, nor were any cytopathic effects (CPE) apparent by microscopic analysis. Based on the
reduction in IFN- production from pDCs after exposure to high titers of B virus from lysed infected
cells, we hypothesized that B virus infects pDCs, perhaps abortively since no CPE was observed. To test
this hypothesis, we exposed purified pDCs to B virus infected cell lysates (MOI 10) in 50ul in medium and
cultured for 1h at 37C, 5% CO2 to allow for adsorption. After 1h, 150ul of medium was added and pDCs
were cultured for an additional 23h. To accurately quantify any changes in B virus titers after 24h, input
virus used to infected pDCs along with harvested supernatants were stored at -80C for analysis. Samples were freeze-thawed two times prior to titering by standard plaque assay on Vero cells. As shown in
Figure 20 Box A, the titer of B virus in pDCs after 24h was 2x105 pfu/ml while the input titer was 7x105
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pfu/ml at 1hpi. The reduction of virus after 24h was not significant by paired student t-test, but clearly
shows that pDCs do not support productive infection. This slight reduction in titer was expected because
dendritic cell can endocytose and destroy virus particles.
Prior to entry, B virus attaches to the surface of the cell via specific receptors. This stage of virus
infection is referred to as adsorption in which virus particles are bound to receptors but have not entered the cells. To determine if the titers from pDCs at 24h were due to replicating virus, or because virus particles were bound to the surface and had not entered the pDCs, we modified the experiment to
include a 50mM citric acid wash, which inactivates any bound virus particles that have not entered the
pDCs. The same experimental setup was used except with the addition of a citric acid wash for 10min
after the 1h adsorption step. pDCs were washed twice prior to re-suspension in 200ul of medium and
incubated at 37C for 23h and titers were quantified by standard plaque assay. As previously, an input
titer was collected at 0hpi, upon the addition of B virus to the pDCs. As shown in Figure 20 B, the titers in
pDCs after 24h was reduced to zero and the input titers were 2x105 pfu/ml. These data indicate that B
virus failed to replicate within pDCs and the titers previously observed at 24hpi, were likely adsorbed
virus particles that failed to enter cells, remaining bound to the pDC surface.
To further investigate whether pDCs support early events of virus infection and subsequent viral
DNA replication, we quantified B virus replication by measuring B virus DNA copy numbers. To do this,
we exposed pDCs to B virus (MOI 10) for 1h at 37C, in a humidified 5% CO2 incubator. After adsorption,
unattached virus was removed by centrifugation at 400xg for 10 min. pDCs were re-suspended in 200ul
of medium and incubated for an additional 23h, after which and cells and supernatants were collected
in an equal volume of Solution A provided in the Invitrogen DNA Isolation Kit, and DNA was isolated according to the manufacturer instructions. The gene encoding glycoprotein B (gB) was amplified as a
marker of DNA replication as the greater the numbers of viral genomes replicated, the more copies of
gB DNA. Quantitative real-time PCR was used to assess the numbers of gB DNA copies present within B
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virus exposed pDCs, both in our input collected at 1hpi and output 24hpi. The gB gene was amplified
using forward and reverse primers and detected using the internal sequence specific probe of FAMTAMRA. To quantify the gB copy numbers in pDCs exposed to B virus, a standard curve was generated
using known concentrations of plasmids containing the gB gene. As shown in Figure 20C, the number of
gB DNA copies in pDCs at 24h was 3.5x108 and in pDCs at 1h was 2x108. The increase in DNA copy numbers at 24h was not significant by paired student t-test further confirming that B virus does not productively infected pDCs.
In all of the experiments so far we have measured late stages of viral infection, either intact virion production (plaque assay) or DNA replication (gB DNA). Presumably in the absence of viral DNA replication, early events post-infection have been blocked to some extent. To determine whether B virus
abortively infects pDCs, we used a standard reverse-transcriptase PCR to measure viral gene expression
at throughout infection. To do this, we exposed pDCs to B virus (MOI 2) for 2h, 4h, or 6h at 37C, in a
humidified 5% CO2 incubator. Because we were amplifying RNA transcripts, it was not necessary to remove virus after adsorption. pDCs were incubated for the respective times and cells were pelleted by
centrifugation at 400xg for 10min. The cell pellets were resuspended in 200ul Tri-Reagent and RNA was
isolated according to the manufacturers instructions. A One-Step reverse transcriptase PCR was conducted to convert RNA into cDNA, then using specific primers for B virus genes of immediate-early
(ICP0), early (TK) and late (gC) were amplified. Amplification samples were electrophoresed on a 1.5%
acrylamide gel containing ethidium bromide for DNA detection. As a positive control, we used HFFs infected for 24h with B virus (MOI 10) to confirm transcript detection. A negative control of water was
used to detect contamination. ICP0 is an immediate-early (IE) gene and during productive infection the
expression reaches peak levels at 2-4hpi. As shown in Figure 20D, ICP0 gene expression in B virus exposed pDCs was restricted, as a very light band was visible at 4 and 6hpi, but was not near the intensity
of our positive control. Thymidine kinase (TK) was used as a measure of early gene expression, which

65
during productive infection peaks around 6hpi. At no time point in B virus exposed pDCs was TK gene
expression detected, but it was present in the positive control. Lastly, gC was used as measure of late
gene expression. We expected to see no gC transcripts since we did not detect any viral replication (gB
DNA) or infectious virions (plaque assays) and as expected we did not see gC transcripts in B virus exposed pDCs. These data indicate that pDCs do not support productive replication of B virus and infection
is abortive at the IE stage of the B virus life cycle. Combined, all of these data confirm that B virus does
not productively infect pDCs, since B virus titers are not increased after 24h (Figure 20A and B), that B
virus gB copy number do not increase significantly after 24h (Figure 20C), and that early and late B virus
genes are not expressed (Figure 20D). Based on these data, we can conclude that the lack of IFN- production from pDCs exposed to high titers of B virus was not due to virus replication.
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Figure 20 pDCs do not support productive B virus infection
A. pDCs were cultured with B virus (MOI 10) for 0 and 24h and B virus titers were measured by standard plaque assay.
B virus titers were not reduced significantly within 24hpi.
B. pDCs were cultured with B virus (MOI 10) for 1h, then washed with citric acid and cultured for 23h and B virus titers
were measured by standard plaque assay. B virus titers were reduced to zeroafter 24h.
C. pDCs were cultured with B virus (MOI 10) for 1h, unadsorbed virus was removed and cultured for 24h. DNA was
purified and qRT-PCR was used to measure gB DNA copy numbers, which were not significantly increased after 24h.
D. pDCs were cultured with B virus (MOI 2) for 2, 4, and 6h. RNA was isolated from cell pellets. B virus transcript
expression was detected using reverse-transcriptase PCR and run on a acrylamide gel. A positive control of B virus
infected HFFs were used. NS=not significant.

3.5

Macaque and human PBMCs fail to produce IFN- in response to B virus infected fibroblasts
Understanding the role of individual immune cell types is important for defining direct effects of

virus infection, but there are many indirect effects mediated by the interplay with and between other
defense cells. The pDCs are a specific subset of dendritic cells that as we have shown in Figures 16 and
17, respond to B virus infected fibroblasts by producing IFN-, TNF- and IP-10. We have reviewed how
each of these molecules impacts other defense cells. The levels of each is limited, however, when compared to direct exposure to B virus infected lysates after which human pDCs produced significantly more
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IFN-, TNF-, and IP-10, as well as IL-1, IL-6, IL-8, and MIP-1/. The restriction of cytokine production
in human pDCs exposed to infected cells was not due to limited virus exposure due to syncytial formation in fibroblasts, because we have shown that titers were similar in the supernatants of co-cultures
and infected cell lysates (Figure 18) or due to B virus infection of pDCs (Figure 20), which we have shown
is non-productive. One of our original purposes of the research presented in this dissertation was to
compare the natural and foreign host response to B virus in relationship to role(s) of pDCs. Macaques
are the natural host for B virus and the data available on how they respond to B virus is extremely limited. To contribute to the overall knowledge of the macaque response to B virus, we explored the macaque pDC response to B virus, however, pDC studies in macaques are difficult due to limited availability
of blood and a lack of pDC isolation reagents and experimental infections require BSL-4 facilities. To
measure the pDC response to B virus in macaques using our cell culture model, we measured IFN- production from macaque PBMCs exposed to B virus infected cell lysates and compared these data to the
IFN- production from pooled human PBMCs (Figure 21) and human pDCs (Figure 19) exposed to B virus
similarly. Because there are no available reagents for the isolation of macaque pDCs, and because macaque PBMCs contain similar numbers of pDCs as humans [211], we used IFN- production from human
PBMCs (Figure 21) to correlate the amounts of IFN- produced from pDCs (Figure 19) in macaque
PBMCs. Human pDCs produced about 30 fg/cell of IFN- when exposed to an MOI of 5 (Figure 19), and
assuming that pDCs are 0.1% of total PBMCs, the PBMCs made approximately 46 pg/ml (46,000 fg/ml; or
46 fg/pDC; Figure 21), which was nearly equivalent to the IFN- produced by purified pDCs. These data
support numerous observations that pDCs produce the majority of IFN- in spite of the fact that they
comprise less than 0.1-0.8% of the PBMCs. Based on these data, IFN- production from macaque PBMCs
was used to correlate pDC cytokine production in macaques. The additional IFN- produced from B virus
exposed human PBMCs can be attributed to other cell types that make IFN- such as myeloid dendritic
cells, but we did not explore these specific sources of IFN- in our studies. The percentage of immune
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cell types in PBMCs varies depending on individual immune responses. Whole blood contains leukocytes
(immune cells), erthrocytes (red blood cells, RBC) and platelets. Ficoll-Density Centrifugation allows the
separation of leukocytes from other blood products. Leukocytes comprise approximately 0.1-0.2% of
blood cells. Of these leukocytes, T cells make up approximately 7-14%, B cells make up 1-7%, NK cells
are 1-6%, myeloid cells, which include DCs, make up 53-86% and monocytes make up 2-12%. The granulocytes (35-80%) are typically removed from the leukocyte population during gradient centrifugation as
they pellet with RBCs and platelets. We measured IFN- production from macaque PBMCs following
direct exposure to B virus infected cell lysates and in co-cultures with B virus infected RMFs. Based on
the characteristic of the rapid and robust induction of neutralizing antibodies in macaques after B virus
infection, we hypothesized that B virus infected macaque co-cultures would induce robust amounts of
IFN- from PBMCs, while human co-cultures would be restricted.
Rhesus macaque fibroblasts were not commercially available at the time of these studies, so in
order to test the macaque response we first had to establish and characterize a rhesus macaque fibroblast cell line from whole skin biopsies obtained from Yerkes Primate Center. We designate these are
rhesus macaque fibroblasts or RMFs. The methods for isolation of RMFs will not be discussed here but
are detailed in the materials and methods. Immunofluorescence was used to confirm fibroblast purity
using the fibroblasts markers vimentin and fibronectin, as well as cytokeratin, a keratinocyte marker
(Figure 31 in Appendix). PBMCs were isolated under sterile conditions from fresh macaque or human
blood using Ficoll-Hypaque gradient centrifugation and stored in liquid nitrogen. At the time of the experiment, PBMCs were quickly thawed, checked for viability and used immediately. For each experiment, PBMCs were used from one individual macaque or human.
To test our hypothesis we setup a co-culture system similar to what we described previously for
human pDCs (Figure 15). RMFs and HFFs were seeded into 96-well plates, grown to sub-confluency and
infected with B virus (MOI 5). At 1hpi, unadsorbed virus was removed and PBMCs were added to each
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well in 200 ul medium and incubated for 23h. Simultaneously, PBMCs were seeded in 50ul of culture
medium into 96-well round-bottomed plates and each treatment was added in 150ul of culture medium. Cells were incubated at 37C, in a humidifed 5% CO2 incubator and at 24hpi cell-free supernatants
were collected by centrifugation at 400xg for 10min. Tween/DOC was added to a final concentration of
1% to inactivate virus. Supernatants were stored at -80C until analyzed by ELISA to measure IFN- levels using the Human IFN- pan ELISA Development Kit (HRP) (MabTech, Cincinnati, OH). This kit detects
11 of the 12 subtypes of IFN- using a sandwich ELISA technique with a capture and a detection antibody conjugated with horseradish peroxidase (HRP). Serial dilutions of a standard provided with the kit
allowed for generation of a standard curve and IFN- concentrations were interpolated using RIA
Spline/LOWESS in GraphPad PrismTM. To ensure the functionality of the PBMCs, we used positive controls known to induce IFN- from PBMCs. For human cells we used HSV-1, as this virus is endemic in
humans as B virus is endemic in macaques, and it is a closely related simplex virus, and a robust inducer
of IFN- from PBMCs. For macaque cells, CpG 2216 (5 g/ml), which is a synthetic DNA molecule that
activates pDCs via TLR9, was added at 1hpi to co-cultures. CpG was used primarily because HSV-1 does
not infect RMFs productively. As negative controls, medium only and MCL were used to measure any
basal response(s) or to how the virus stocks were generated.
As shown in Figure 21 Box A, B virus infected RMFs co-cultured with PBMCs (white bars) failed
to produce significant amounts of IFN- at 11.69 pg/ml. Our positive control of CpG 2216 verified that
macaque PBMCs in co-cultures were capable of producing IFN- with mean levels of 65 pg/ml. When
macaque PBMCs were directly exposed (gray bars) to B virus infected lysates or CpG, each induced 24
pg/ml proving that the PBMCs were responsive to B virus. As expected, neither of the negative controls
induced significant levels of IFN- in co-cultures with RMFs or from direct exposure.
Similarly and as shown in Figure 21 Box B, human PBMCs co-cultured with B virus infected HFFs
failed to produce any significant amount of IFN- at 1.79 pg/ml, but our positive control of HSV-1 shows
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that PBMCs were responsive by producing 6.48 pg/ml of IFN-. Also, human PBMCs directly exposed to
B virus or HSV-1 infected lysates produced 46.59 pg/ml and 107 pg/ml of IFN-, respectively. The response was virus specific as human PBMCs that were directly exposed or in co-cultures with negative
controls did not produce significant amounts of IFN-. It is important to point out that neither human or
macaque fibroblasts produced any detectable IFN- in response to any of the treatments (data not
shown, Brock 2012).
These data show that the host specific PBMC response to B virus infected fibroblasts was similar
between human and macaques. There was a difference in the amount of IFN- produced from PBMCs
after direct exposure to B virus infected lysates. Human PBMCs made twice as much IFN- than macaque PBMCs after direct exposure. Macaques have similar numbers of pDCs in PBMCs as humans [211],
but contain fewer mDCs [212], which may explain the observed reduction in the amount of total IFN-
from macaque PBMCs directly exposed to B virus. Using our correlation of human PBMC induced IFN-
with that of pDCs, we can assume because macaques contain a similar number of pDCs at 0.1% of
PBMCs, that the IFN- should be equivalent to human pDCs. The level of IFN- produced from macaque
PBMCs, however, was half as much as from human PBMCs, indicating that macaque pDCs may respond
differently to B virus, or alternatively, because they have fewer mDCs, show an overall reduction in IFN.
There are limited data available on the PRRs in macaque cells as compared to human cells, but
macaque pDCs express similar levels of TLR7/9 and IRF7 and respond to HSV-1 by producing similar levels of IFN-, when measured by intracellular cytokine staining and ELISPOT [211]. These data suggest
that macaque cells are sensing B virus or viral DNA differently than human pDCs/PBMCs. If this is the
case, then it is crucial to understand the differences between these two hosts, especially considering
that macaques are critical animal models for many human diseases, and with respect to this dissertation, could explain the different outcomes of infection, providing a potential target for therapeutics.

71
To determine whether the amount of virus available in the supernatants of infected fibroblasts
affected the IFN- production by PBMCs, we compared the amounts of B virus available to PBMCs in cocultures. To test this, HFFs and RMFs were infected with B virus (MOI 5) and B virus titers were measured in the supernatants after 24h. B virus remains primarily cell-associated through the fusion of infected cells (syncytia), which limits the amount of cell-free virus within supernatants. As shown in Figure
22, the titers in supernatants from B virus infected RMFs was 4.6x104 pfu/ml, while the titers of B virus
in supernatants of infected HFFs was 1.8x104 pfu/ml, a 2.5-fold difference. B virus titers were much
higher in RMFs within the cell and supernatants than HFFs, as expected. The titer of B virus iin infected
cell lysate-exposed exposed PBMCs was 5x105 pfu/ml, approximately a log greater than in the cocultures. The titers of B virus in the supernatants from RMFs and HFFs were similar, and although the
levels of IFN- produced in co-cultures were not significant, RMFs produced nearly 12 pg/ml while human cells produced only 2 pg/ml. This 3-fold reduction in virus production from HFFs may explain, in
part, the reduction in the levels of IFN- produced from human PBMCs in co-cultures. A dose response
study is required to quantify the ability of PBMCs to make IFN- in co-cultures. As discussed previously,
the quality of virus produced from infected fibroblasts may be different than the virus accessible in the B
virus infected lysates used in direct virus exposure. Additionally, and perhaps more importantly, freeviral DNA is likely present in the infected cell lysates, but this want not measured in our experiments to
date.
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Figure 21 IFN-production from B virus-exposed human and macaque PBMCs
HFFs (human) and RMFs (macaques) were infected with B virus (MOI 5) for 1h and PBMCs were added and cultured
for 24h (White bars). Simultaneously, human and macaque PBMCs were directly exposed to B virus infected cell lysates (MOI 5), as well as to control treatments and cultured for 24h (Gray bars). Cell-free supernatants were collected,
tween/DOC was added to a concentration of 1% to inactivate viruses and IFN- concentrations were measured by
ELISA. UN=medium only; MCL=uninfected cell lysate; HSV-1 MOI of 5; CpG 2216 (5g/ml). Error bars represent SEM.
*p<0.05 by ANOVA with a post-hoc of Newman-Keuls.
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Figure 22 Infectious B virus contained in supernatants/cells of B virus infected human and macaque fibroblasts
B virus titers were measured in the supernatants (sup) and in the supernatants and cells (sup+cells) after 24 hpi to
measure progeny virus from B virus infected (MOI 10) rhesus macaque fibroblasts (RMFs), and human foreskin fibro4
blasts (HFFs). The supernatants from HFFs contained 1.8x10 pfu/ml of B virus while the supernatants from RMFs con4
tained 4.6x10 pfu/ml of B virus. The virus is primarily cell-associated as shown by the titers obtained from superna5
6
tants together with cells at 1.3x10 pfu/ml for HFFs and 1.6x10 pfu/ml for RMFs.

3.6

B virus replication is not sensitive to IFN- produced from virus exposed PBMCs
We have here that human pDCs, as well as human and macaque PBMCs respond to direct B vi-

rus exposure with the production of cytokines and chemokines, albeit the levels of these are lower than
those observed in parallel experiments with HSV-1. We have further evaluated in greater detail, IFNproduction by pDCs exposed to infected fibroblasts versus pDCs exposed to B virus released from infected cell lysates. The levels of cytokines produced by human pDCs, or human and macaque PBMCs, cocultured with B virus infected fibroblasts were significantly lower than the levels in parallel experiments
infected with HSV-1 Figures 16 and 21). These data demonstrate that pDCs are activated by B virus
more so in the presence of infected cell lysates, than in the presence of intact infected cells, however,
pDCs are not activated to the extent that they are in the presence of HSV-1 under similar conditions. To
explore further why B virus infected cell lysates activated pDCs to a greater extent than intact infected
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cells, we speculated that perhaps there was less virus released by the intact infected cells. An explanation for the differences in pDC activation is not evident, but we have shown it is not due to limited
amounts of virus in supernatants of infected fibroblasts (Figures 18 and 22). IFN- is the classic antiviral
compound and has been shown to dramatically reduce HSV-1 titers in vitro. Animals or humans with
defects in their ability to produce IFN- develop encephalitis as a result of HSV-1 infection, which is
normally an innocuous infection in humans. To determine whether there was an antiviral effect of the
IFN- produced from human and macaque PBMCs exposed to B virus released from infected cell lysates,
we quantified the sensitivity of B virus replication to PBMC produced IFN-, with the knowledge that our
data support that the bulk of IFN-was produced from pDCs contained within the PBMC population.
Supernatants from B virus exposed PBMCs either directly exposed or in co-culture with B virus infected
fibroblasts, were tested to determine whether B virus titers from infected fibroblasts were reduced. We
hypothesized that the IFN- produced from B virus-exposed PBMCs will reduce the production of infectious virus from infected fibroblasts, but because PBMC co-cultures lack significant levels of IFN-
these will fail to reduce production of infectious B virus. To test this hypothesis, PBMCs were incubated
with B virus contained within infected cell lysates (MOI 5) for 1 h in a minimal volume of culture medium
supplemented with 2% FBS, after which the cell-culture medium volume was brought to 200 ul and incubated. After 24 h, cell-free supernatants were collected by centrifugation at 400xg for 10 min, in
which any adsorbed virus particles would remain with the cells. RMF and HFFs were grown to subconfluency in a 48-well plate and infected with B virus (MOI 5). After 1 h adsorption, the inoculum was
removed and the supernatants previously collected from the B virus exposed PBMCs were added and
cells were incubated for 23 h. These supernatants contained whatever IFN- was produced by the
PBMCs in response to exposure to B virus infected cell lysates. Infected RMFs and HFFs as well as supernatants from these were collected, frozen and thawed once, and titered by standard plaque assay.
As a control, fibroblasts were treated similarly and cultured without PBMC supernatants. As shown in
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Figure 23, neither human or macaque B virus exposed PBMC supernatants caused a significant reduction
in the levels of infectious virus produced from each respective cell line even in the presence of IFN-
produced by PBMCs directly exposed to B virus (Figure 21). As shown in Figure 23A, B virus titers from
human fibroblasts (A. left graph) at 24 hpi, following culture with supernatants harvested from B virus
exposed PBMC (BV-exposed PBMC) were 5.4x105 pfu/ml, while HFFs treated with MCL-exposed PBMC
(MCL-exposed PBMCs) produced 9x105 pfu/ml, a 0.6 times increase of titer, which was not significant
when analyzed by student t-test. Macaque fibroblasts (A. right graph) showed a similar trend, but the
titers were a log higher than HFFs for when the medium from MCL-exposed PBMC was cultured with
infected RMFs (MCL-exposed PBMC) at 1.2x107 pfu/ml and when B virus-exposed PBMCs medium was
incubated with infected RMFs (B virus-exposed PBMC) there was 1.5 times reduction in titers to 8x106
pfu/ml. B virus titers in both human or macaque fibroblasts when treated with medium from B virus exposed PBMCs were not significant when compared to infected fibroblasts that were treated with medium from MCL treated PBMC when analyzed using a paired two-tailed Student t-test. These data show
that PBMCs exposed to B virus did not significantly inhibit B virus replication in spite of IFN- production
by B virus exposed PBMCs (Figure 21).
A more accurate representative of natural infection is to determine if supernatants from cocultures of PBMCs could suppress B virus replication. We did not expect B virus replication to be reduced
when infected fibroblasts were treated with the supernatants from B virus infected co-cultures, as they
did not produce significant amounts of IFN- (Figure 21). To test this, we infected fibroblasts with B virus (MOI 5) and at 1 hpi, we added PBMCs and cultured for 23 h. As a negative control, we MCL treated
co-cultures at the equivalent and same way as B virus. Cell-free supernatants were collected by centrifugation at 400xg for 10 min. HFFs and RMFs were grown to confluency in a 48-well plate and infected
with B virus (MOI 5). At 1hpi, unadsorbed virus was removed and the PBMC co-culture supernatants
were added to infected fibroblasts and cultured for 24 h. As shown in Figure 23B and as expected, B vi-
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rus titers were not significantly reduced when cultured with supernatants from B virus infected PBMC
co-cultures. B virus titers in HFFs (B. Left graph) treated with supernatants from PBMCs co-cultured with
B virus infected HFFs (BV PBMC Co-cultures) and MCL infected HFFs (MCL PBMC Co-cultures) showed a
similar titer at 3.0x105 pfu/ ml. Again, the trend was conserved in macaques as the titers for RMFs treated with supernatants from B virus infected co-cultures (BV PBMC Co-cultures) or MCL treated cocultures (MCL PBMC Co-cultures) were the same at 3.0x106 pfu/ml, a log higher than HFFs. These data
were what we expected because the co-cultures did not produce significant amounts of IFN-. Overall,
these data indicate that B virus exposed PBMCs, either directly exposed to B virus, or in co-cultures with
infected fibroblasts, fail to limit B virus replication in fibroblasts in either host. These data were unexpected especially for macaque PBMCs because B virus is endemic in these animals, we predicted that
these could limit B virus replication in cells derived from the primary sites of infection. These data make
it clear that B virus is resistant to PBMC induced IFN- in either host.
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Figure 23 B virus exposed PBMC supernatants do not reduce B virus titers in fibroblasts
A. Supernatants from B virus exposed PBMCs do not reduce replication in B virus infected fibroblasts. PBMCs were
exposed to B virus (MOI 5) or MCL for 24h. The supernatants were transferred to B virus infected fibroblasts (MOI 5)
at 1hpi and cultured for 23h and titers were measured (BV-exposed PBMC). A negative control of MCL treated PBMCs
were used (MCL-exposed PBMC). Titers are shown in the table on the right.
B. Supernatants from B virus infected PBMC co-cultures do not reduce B virus replication in infected fibroblasts. Fibroblasts were infected with B virus (MOI 5) and at 1hpi, PBMCs were added and cultured for 23h. Cell-free supernatants were transferred to freshly infected fibroblasts (MOI 5) and cultured for 23h and titers were determined. The
medium from co-cultures of PBMCs with B virus infected fibroblasts was transferred to B virus infected fibroblasts (BV
PBMC Co-cultures) and titers were measured after 24h. As a control, B virus infected fibroblasts were treated with
MCL treated fibroblasts co cultured with PBMC (MCL PBMC Co-cultures). The tables on the right show the titers at
each treatment.

3.7

Sensitivity of B virus replication in infected macaque and human cells to recombinant IFN-
To consider the possibility that B virus replication may not be sensitive to the levels of IFN- pro-

duced by PBMCs exposed to B virus infected cell lysates (46 pg/ml), we considered, with the high MOI of
5, that the IFN pathway, overwhelmed by large amounts of virus, could not effectively block the production of B virus progeny in newly infected cells. We hypothesized that the efficacy of the IFN-antiviral
activity is dependent on the IFN- dose and the amount of infectious virus to which a cell is exposed.
To test this hypothesis, we pre-treated fibroblasts with universal Recombinant Type I IFN (PBL Interferon
Source, Piscaway, PA) at varying concentrations ranging from 12.5-50 U/ml for 30 min prior to infection.
The IFN-treated HFFs and RMFs were then infected with B virus at a low MOI of 0.01 or high MOI of 5.
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Unadsorbed virus was removed and cells were cultured in the presence of IFN-for an additional 23 h.
Cells were collected by scraping into the medium followed by freeze-thawing and titering by standard
plaque assay. The purpose of using a low MOI was to allow for a natural scenario where IFN- binds to
bystander cells to provide some protection by blocking virus replication, whereas the high MOI was used
to ensure maximal infection of all cells to determine whether IFN-could block de novo production of
progeny virus.
As shown in Figure 24, B virus replication in HFFs or RMFs was not significantly reduced, whether
the infection was a high or low MOI, and regardless of the dose of IFN. B virus titers in HFFs infected at
an MOI of 5, in the absence of IFN- treatment were 2x106 pfu/ml. At the lower MOI of 0.01, HFF titers
were reduced to 2x105 pfu/ml without IFN- treatment. Virus titers were reduced to 5x104 pfu/ml, a 4fold reduction, when HFFs infected (MOI 0.01) were treated with 12.5 U of IFN- but this reduction was
not significant when analyzed by ANOVA. At 25 U and 50 U, the virus titers in HFFs at an MOI of 0.01
were nearly the same as untreated at 1x105 pfu/ml and 3x105pfu/ml, respectively. At higher MOI 5 infectiouns, infectious virus produced in HFFs, that were not treated with recombinant IFN-a, were present at a log higher than at the lower MOI of 0.01, with a similar drop in titers in the 12.5 U IFN treated
group at 8x105 pfu/ml, but was not significant when analyzed using ANOVA. RMF titers at MOI 0.01 and
MOI 5, were nearly the same without IFN- treatment and at all doses of recombinant IFN-, but were
not significantly different at 1x107 pfu/ml. We expected the amount of virus progeny to be reduced in
response treatment of cells prior to and throughout infection with higher doses of recombinant IFN-
particularly when infections were performed with low MOIs but the response was similar regardless of
the amounts of recombinant IFN- and virus in both host cell species. The levels of recombinant IFN-
in each of the treatments were much higher than we observed from our PBMCs (Figure 21). According
to the manufacturer, PBL Interferon Source, 1 U of Universal Type I IFN has an activity of approximately
38 pg/ml of IFN, so 12.5 U represents 475 pg/ml of IFN, which we did not observe in any of the PBMC
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cultures, either directly or in co-cultures, however it is shown later that these low levels are sufficient to
activate STAT-1, which is downstream of the IFNR. Even at artificially high levels of recombinant IFN-,
B virus replication was not significantly reduced in either macaque or human cells. We expected that B
virus titers would be lower in the natural host cells, but these data clearly show that IFN- does not
block B virus replication. This is an important observation suggesting that the amount of virus produced
during infection is likely a factor in different pathogenesis outcomes in macaques and humans, but rather other controllers or lack thereof, of the effects of produced virus play more important roles in the
differential pathogenesis observed between macaques and humans in vivo, because at least at the site
of entry, virus replication is unfettered in the presence of PBMC produced IFN-or recombinant IFN-

Figure 24 B virus titers are unaffected by recombinant IFN-
Fibroblasts were pretreated with Universal Type I IFN for 30min, after which they were infected with B virus at different MOIs. Cells were cultured for 24h with IFN and titered by standard plaque assay to quantify progeny virus produced from macaque and human fibroblasts. NS=not significant by student t-test.
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3.8

Medium from B virus exposed PBMCs activates the Type I IFN signaling pathway in uninfected
macaque and human fibroblasts
We have shown that B virus titers were not reduced in HFFs or RMFs when cultured with medi-

um from B virus exposed PBMCs (Figure 23), so we wanted to know next whether IFN-produced by B
virus exposed PBMCs (Figure 21) is functionally active and sufficient to activate the IFN-signaling
pathway in uninfected fibroblasts. Because the titers of B virus were unaffected in the presence of IFN-
in B virus exposed medium from PBMC exposed to B virus infected cell lysates, we hypothesized that B
virus induced IFN-a produced by PBMCs is not functional and does not activate the IFN-signaling
pathway in healthy fibroblasts from either macaque or human species. Under normal, healthy conditions, type I IFN signaling pathway is activated upon binding of IFN-/ to the IFNR. HSV-1 has been
shown to target the IFN receptor for degradation as a mechanism to limit the IFN response [213], but
when HFFs and RMFs were infected with B virus (MOI 5), the IFNaR levels were not changed when compared to MCL treated cells (data not shown, N. Brock, 2012). Ligand:receptor binding activates Janus
kinases (JAK), of which there are four members (JAK1, JAK2, JAK3, and TYK) to recruit and phosphorylate
STATs, of which there are 7 family members (STAT1-6; STAT 5a, 5b). Activated STATs then form a homoor heterodimer that complex with an interferon regulatory factor to become an interferon stimulated
gene factor (ISGF). In the case of Type I IFN signaling, the transcription factor complex is designated
ISGF3, which is composed of a heterodimer of STAT1/2 and IRF9. The ISGF enters the nucleus via specific
nuclear membrane transporters and binds to specific promoter regions within DNA designated interferon response elements (ISRE). The trans-activating domain, located at the C terminus of the STAT molecules can recruit other transcription factors and co-factors to mediate interferon-dependent gene expression. Once the genes are activated, phosphatases within the nucleus can remove the phosphate
groups from the STATs to turn off gene transcription. The de-phosphorylated STATs are shuttled back to
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the cytoplasm and assuming the activating signal, in our case, IFN-, is still bound to the receptor, STATs
can be reactivated by phosphorylation via JAKs. This process continues until the activating signal is no
longer available, or if an antagonistic molecule, such as the suppressor of cytokine signaling (SOCS), or
the protein inhibitor of STAT (PIAS), whose expression is IFN dependent, interferes with the pathway.
For our experiments, we used STAT-1 phosphorylation as a measure of IFN-signaling as a result of
treatment of healthy cells with medium collected from B virus exposed PBMCs. STAT1 can be alternatively spliced to generate two isoforms, STAT1 (91kDa) and STAT 1 (84kDa). The functions of the
splice variants are not well known, but in the context of Type I IFN signaling, the variants appear to function similarly. STAT-1 lacks the transactivation domain, which would prevent the tethering of transcription factors after promoter binding, potentially directing a different gene expression profile than from
that engaged as a result of STAT-1. Lodige et al reported in a study of IFN- treated HeLa cells that
STAT1 was not different than STAT-1 in the ability to bind to the JAKs, but that the nucleocytoplasmic
shuttling of STAT-1 was slower, and that STAT-1 was more prevalent at lower levels of IFN- [214].
STAT-1 can undergo numerous post-translational modifications such as glycosylation, acetylation and
phosphorylation all of which can influence the interactions with JAKs, other STATs, IRFs, ISGF promoter
binding, transcription factor recruitment and IFN dependent gene expression. For our purposes, we
used the phosphorylation of STAT-1 at tyrosine 701 as a marker of activation of STAT-1 and did not explore any other modifications.
To test our hypothesis that IFN- from PBMCs does not activate the IFN-signaling pathway we
incubated human and macaque PBMCs with infected cell lysates containing B virus (MOI 5) for 24h. To
confirm that the PBMCs could produce IFN-, we added CpG 2216 at 5ug/ml to healthy PBMCs, which
subsequently can induce IFN- from pDCs in a TLR9 dependent manner. We used two negative controls
for IFN- production from PBMCs, medium only and MCL, in equivalent amounts to the B virus exposed
PBMCs. We cultured with PBMCs with treatments for 24h and supernatants were collected by centrifu-
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gation at 400xg for 10min. To determine if medium from the infected or control PBMCs (supernatants)
could activate STAT-1 phosphorylation (p-STAT-1) in uninfected fibroblasts, RMFs and HFFs were grown
to sub-confluency in 48-well plates and the cell-free supernatants transferred to uninfected fibroblasts.
As a positive control for p-STAT-1, we treated uninfected fibroblasts with 50 U/ml of recombinant IFN. At specific times, medium was removed and cells were collected in 50ul of Laemmli buffer containing
2- -mercaptoethanol and the samples were stored at -80°C. To determine if STAT-1 was phosphorylated, an SDS gel was run using 7.5% polyacrylamide, with equal loading by volume of the cell lysates
(which was confirmed by using GAPDH as a loading control). Subsequently, the proteins were electroblotted onto nitrocellulose (0.45 m), blocked and then probed using anti-phospho (Y701)-STAT-1, total
STAT-1, and GAPDH as a loading control. As shown in the left box of Figure 25, human fibroblasts treated for 1h with medium collected from B virus exposed PBMCs did activate-STAT-1 via phosphorylation,
demonstrating that the levels of IFN-were sufficient to initiate this pathway. As discussed previously,
STAT-1 can be alternatively spliced to produce two isoforms, and HFFs exposed to medium collected
from B virus exposed PBMCs resulted in the p-STAT-1/ present at similar levels. Our positive control
of CpG treated PBMCs, also induced p-STAT-1 and  within 1 h post treatment, similarly to HFFs treated with medium from B virus exposed PBMCs. Although our MCL treated PBMCs failed to produced any
detectable levels of IFN- (Figure 21), we saw very weak p-STAT-1 Our positive control of IFN treated
HFFs, resulted in activation of both isoforms but levels of p-STAT-1 were greater. At 3 h following exposure to medium from B virus exposed PBMCs, HFFs showed a higher intensity band for p-STAT-1
relative to what was observed at 1 h post treatment. The p-STAT-1levels for MCL were unchanged at 3h
and the IFN--treated fibroblasts showed a reduction in intensity of p-STAT-1with theisoform
much weaker than observed in the samples collected at 1h. An interesting observation is that while all
total STAT-1 levels were equivalent across samples, HFFs only expressed STAT-1for total STAT-1. These
results indicate that human PBMCs exposed to B virus can activate the IFN- signaling pathway and that
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B virus induces the expression of the STAT-1  isoform. The major producer of IFN-in PBMCs, are
pDCs.
To compare the macaque response, as shown on the right box in Figure 25, macaque PBMCs exposed to B virus infected cell lysates were able to induce p-STAT-1 in uninfected RMFs at 1h, and unlike humans did not induce the  isoform. Our negative control of MCL induced a low amount p-STAT1 and our positive control of CpG treated PBMCs induced low levels of p-STAT-1 RMFs treated with
IFN-induced both isoforms of p-STAT-1, although the  isoform was present at higher levels, where
HFFs only induced the  isoform. There was an apparent delay the appearance of p-STAT-1, as the intensity of the band was greater at 3h post treatment than at 1 h for RMFs. The medium collected from
CpG-treated PBMCs failed to increase the levels of p-STAT-1 at 1 h and only activated the  isoform. The
IFN-treated RMFs showed a greater intensity of the p-STAT-1 band at 3 h and additionally activated
the  isoform. Interestingly, RMFs appear to have a basal level of STAT-1 that is not present in HFFs as
total levels of STAT-1 of both isoforms were equal. This is a crucial observation because while there are
limited data on the functions of the different isoforms, it is clear that RMFs and HFFs respond differently
to IFN-stimuli, and treatment with medium from B virus exposed PBMCs resulted in differential activation of STAT-1 isoforms in HFFs and RMFs. While we have shown that both macaque and human PBMCs
produce IFN- in response to B virus (Figure 21), we have shown here that the IFN- in medium from
these activates the IFN- signaling pathway in uninfected cells (Figure 25). We know that B virus replication is unaffected by medium collected from B virus exposed PBMCs (Figure 23), but the differential activation of STAT-1 isoforms between species will be explored in the near future as these differences may
result in dramatic differences in IFN-dependent gene expression in each host. This differential effect will
potentially inform differences in the pathogenesis of B virus infection in macaques and humans, and can
be partially investigated in co-culture model systems in the absence of adequate small animal models.
Data from such studies can provide insight into potential transgenic animals that may provide in vivo
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models to study B virus infections with pathogenesis patterns similar to those observed in infected macaques or humans.

Figure 25 Medium from PBMCs exposed to B virus activates Type I IFN signaling in uninfected
fibroblasts
Fibroblasts derived from macaques and humans were cultured with medium collected from B virus exposed PBMCs
for 1 and 3h. Fibroblast lysates were collected in 50 ul and run on a 7.5% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane and probed for p-STAT-1 and total STAT-1, as well as for housekeeping protein GAPDH
Sup=supernatant (medium), MCL= mock cell lysate, BV: B virus, IFN=recombinant IFN-50U/ml, CpG= CpG 2216
5g/ml

3.9

Cell-culture medium from PBMCs co-cultured with B virus infected human or macaque
fibroblasts activates Type I IFN signaling pathways in uninfected fibroblasts of each respective
species
We showed previously that PBMCs co-cultured with B virus infected fibroblasts do not produce

significant amounts of IFN- and that co-culturing infected fibroblasts with medium from these PBMCs
did not reduce B virus replication. To explore a possible mechanism of B virus resistance to IFN- in fibroblasts in light of the observations that co-cultures failed to produce significant amounts of IFN-, we
hypothesized that medium from PBMCs co-cultured with B virus infected fibroblasts fails to activate
the IFNR signaling pathway. We predicted that medium from these co-culture models representing
interactions in humans or macaques at the site of infection would fail to induce STAT-1 activation, or pSTAT-1, because the IFN- levels were not significant when compared to mock cell lysate treated co-
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cultures (Figure 21). To test this hypothesis, we infected fibroblasts with an MOI of 5 of B virus. At 1 hpi,
we added PBMCs and incubated these co-cultures for an additional 23 h. The cell-free medium was
transferred to uninfected fibroblasts and incubated for 1h. Treated uninfected fibroblast lysates were
prepared and analyzed by western blot assay to assess total STAT-1 and p-STAT-1 relative levels. As a
negative control, medium collected from MCL treated PBMC co-cultures were used to ensure the IFN-
production and subsequent p-STAT-1 was due to virus, not to cell lysate. Two positive controls were
used, one, which was CpG 2216 (5g/ml), to ensure the PBMCs in co-cultures could induce IFN-, and
the second positive control was Universal Recombinant Type I IFN, which was added to the uninfected
fibroblasts to ensure that the fibroblasts were capable of activating the IFNR signaling pathway. As
shown in Figure 26, medium from human PBMCs co-cultured with B virus infected human fibroblasts
activated STAT-1, indicating that the IFN- released into medium from B virus infected co-cultures was
sufficient to activate the IFN pathway. Our positive control for IFN- production, CpG 2216, also activated STAT-1 in human cells, leading us to assume that IFN- was the activator of STAT-1 in this experiment. We did see, however, that medium from mock cell lysate treated PBMCs co-cultured with infected fibroblasts activated STAT-1. As we showed in Figure 25, medium from PBMCs treated with mock cell
lysate and co-cultured with B virus infected fibroblasts also produced IFN- which activated STAT-1, as
confirmed in this experiment. Later studies, using a multiplex assay for 26 human chemokines and cytokines, showed that human PBMCs treated with MCL and co-cultured with B virus infected HFFs, produced significant levels of IL-6 (data not shown, M. Vasireddi), which is also known to activate STAT-1 B
virus exposed human PBMC co-cultures also induced IL-6, but the levels were lower than those produced by PBMCs treated with mock cell lysates. The results from this experiment, indicate that the medium from human PBMC co-cultures with B virus infected human fibroblasts activate STAT-1, and thus
the IFN-pathway in uninfected human cells, but the activation is most likely due to the high amounts
of IL-6 in the supernatants, not the low levels of IFN- present in this particular treatment group.
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The macaque response is quite different from the human response, in that the supernatants
from macaque PBMCs co-cultured with B virus infected fibroblasts activated STAT-1 poorly. In contrast
to humans, the supernatants from MCL treated co-cultures did not induce any STAT-1 activation leading
to the conclusion that macaque PBMCs are not activated by cell lysates. The cell lysates in all of our experiments were produced using Vero cells, which were also used to produce all B virus and HSV-1 used
in the experiments described in this dissertation. It is possible that since African Green Monkeys from
which Veros are derived, are not sensed as foreign activating stimuli, because these Old World Monkeys
are more closely related evolutionarily to macaques. To rule this out, additional experiments will be
performed in the near future with virus and lysates prepared from human and macaque fibroblasts. But
these results hint at the possibility that under the experimental conditions, macaque cells did not produce IL-6, but this will be evaluated again in additional experiments in the near future, not as part of this
dissertation. Our data show that RMFs respond to IFN- through the activation of STAT-1, albeit only
weakly under the experimental conditions established. The positive control for IFN- production from
PBMCs, CpG 2216, led to only faint activation of STAT-1(Figure 26), which was not expected since our cocultures with CpG 2216 induced greater levels of IFN- than did B virus co-cultures (Figure 21). The faint
bands for both B virus and CpG 2216 may be due to the short treatment interval, but additional experiments will be required to evaluate this further. In Figure 25, we showed that RMFs had a higher intensity
band for STAT-1 at 3h than at 1h, indicating that the temporal control of the signaling pathway in RMFs
may be different from that in HFFs. Because we measured STAT-1 activation at 1hpe by PBMC so-culture
medium shown in Figure 26, we can hypothesize that the activation of STAT-1 would be increase at 3h.
The co-culture model system we have used for these experiments is a great tool for understanding how B virus infection modulates host immune responses at a cellular level, but these studies must be
extended to evaluate multiple cell types and their interactions in a complex defense system. Our data
provide for the first time knowledge that IFN-is produced from pDCs, and that PBMCs can be used in
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their place when reagents are lacking for the enrichment of pDCs in species, e.g., macaques and other
nonhuman primates. We also now understand that the produced IFN-activate IFNR signaling pathways in human and macaque fibroblasts, each which are critical cells at the site of virus entry, but to
what extent and how these pathways are modulated downstream remains to be investigated in future
studies to unravel the impact of this pathway on the pathogenesis of natural and zoonotic infection .

Figure 26 Supernatants from PBMC co-cultures activate Type I IFN signaling in uninfected fibroblasts
Fibroblasts were cultured with supernatants from PBMC co-cultured with B virus infected fibroblasts for 1h. Cell lysates were collected in 50ul and run on a 7.5% polyacrylmide gel, transferred to a nitrocellulose membrane and
probed for p-stat1. Sup=supernatant, MCL=mock uninfected mock cell lysate, BV: B virus, IFN=recombinant IFN
50U/ml, CpG= CpG 2216 5g/ml

3.10 B virus infection of macaque and human fibroblasts does not activate or block Type I IFN
signaling
In an effort to understand the resistance of B virus to the effects of IFN-, derived from either
PBMC supernatants, PBMC co-cultures or recombinant IFN- treatment during low or high MOI infections across a range of IFN-doses, we then hypothesized that B virus blocks the Type I IFN signaling
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pathway in fibroblasts. The type I IFN receptor is activated upon binding by either IFN- or IFNleading to the activation of JAK and STATs. We used the phosphorylation of STAT-1 as a measure of
IFNR ligation and signaling activation. In the first experiment, we addressed the question of whether B
virus activated, either directly or indirectly, the Type I IFN pathway in RMFs or HFFs. We know that neither RMFs nor HFFs produce Type I IFNs during B virus infection, so we predicted that B virus infection in
these cells does not result in the activation of STAT-1. To test this hypothesis, we infected fibroblasts in
T25 flasks with an MOI of 5 for 24 h. We collected both the supernatant and infected cells at 0, 2, 4, 6
and 24h to measure both IFN- production and STAT-1 phosphorylation (p-STAT-1). As predicted, at all
times post-infection, B virus did not activate the type I IFN signaling pathway through p-STAT-1 in either
RMFs or HFFs (Figure 27). As a negative control, we exposed fibroblasts to uninfected mock cell lysates,
which also did not induce p-STAT-1. Additionally, we measured total-STAT-1 levels to ensure the presence of STAT-1 protein in B virus infected lysates and to confirm that B virus did not degrade STAT-1
(Figure 27).

Figure 27 B virus infection does not activate Type I IFN signaling in human or macaque fibroblasts
Fibroblasts were infected with B virus (MOI 5) in 24-well plates. Cell lysates were prepared and collected in 50ul
Laemmli buffer and electrophoresed on a 7.5% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane and
probed for total STAT-1, p-STAT-1, and GAPDH. MCL=mock uninfected mock cell lysate BV: B virus MOI of 5
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Our data so far, indicates how B virus titers are not affected by IFN- present in medium from
PBMCs exposed to B virus infected lysates (Figure 23) or to recombinant IFN- treatment (Figure 24). In
an effort to explore the mechanism that B virus titers are not affected by IFN-, we hypothesized that B
virus blocks IFN signaling by blocking the activation of STAT-1 in fibroblasts. To test this hypothesis, we
infected human and macaque fibroblasts in 24-well plates with B virus at an MOI of 5 and after 1 h adsorption we added 500 U/ml of recombinant type I IFN for 30 min. The cells were lysed and collected for
analysis by western blot assay for the presence of total STAT-1, p-STAT-1, and GAPDH. As a negative
control, MCL treated cells were used and for a positive control for p-STAT-1 activation, mock cell lysate
treated cells were also treated with recombinant type I IFN (500 U/ml). The data from representative
experiments, shown in Figure 28, indicate that B virus does not block the activation of STAT-1 by the
added recombinant IFN-, as levels were equivalent between MCL and B virus infected cells treated
with IFN, but IFN-is not produced in mock or B virus exposed fibroblasts. Recombinant IFN treatment
increased total STAT-1 levels in both B virus infected cells and mock infected cells. GAPDH was used as a
loading control and was equivalent across all samples. These data show that B virus did not block the
activation of the type I IFN pathway in human or macaque fibroblasts. Previous data from our lab indicate that the interferon stimulated gene expression is not increased during B virus infection in HFFs
[215], providing further confirmation of our results showing B virus resistance to IFN- treatment. Based
on these data, we can hypothesize that B virus blocks the IFN signaling pathway downstream of STAT-1
activation, and most certainly it is necessary to compare ISG expression in macaques because of the differential activation of STAT-1 isoforms.
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Figure 28 B virus does not block the activation of the Type I IFN signaling pathway in macaque
or human fibroblasts
Fibroblasts were infected with B virus at an MOI of 5 for 1h then treated with 500U/ml of IFN for 30min. Cell lysates
were prepared and collected in 50ul of Laemmli buffer and run on a 7.5% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane and probed for p-STAT-1, total STAT-1 and GAPDH.MCL=mock uninfected mock cell lysate,
BV= B virus, +IFN w= 500U/ml IFN for 30 min
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CONCLUSIONS

B virus, a simplex virus closely related to HSV-1, is endemic in macaques of all species and is capable of causing fatal zoonotic infection in humans in up to 80% of cases, if not treated quickly enough
after infection. Identifying the immune correlates of infection in both the natural and foreign hosts will
allow us to develop therapeutics and prophylaxis against B virus infection. This dissertation aimed to
address the defect in human immune responses to B virus infection, specifically the interferon response
and the role(s) of pDCs during infection. Based on the observations that zoonotic B virus infection results
in a delayed or ineffective immune responses and the knowledge of the importance of the IFN pathway
in virus infections, we hypothesized: B virus modulates the IFN response during zoonotic infection by
blocking plasmacytoid DC activation and subsequent IFN signaling pathways to circumvent host defenses, while these pathways remain intact in the macaque hosts.
The results from this dissertation disprove my hypothesis as shown by the data, for the first
time, that human and macaque PBMCs produced similar amounts of IFN- in response to direct B virus
exposure, however, IFN- production was significantly reduced when human pDCs (and PBMCs) were
co-cultured with B virus infected fibroblasts as well as for macaque PBMCs co-cultured with B virus infected fibroblasts, as currently there are no reagents available for the isolation of pDCs from macaques.
Further, both human and macaque fibroblasts continued to support B virus replication when treated
with IFN-, either from endogenous (B virus-exposed PBMCs) or exogenous (recombinant IFN) sources
despite the activation of the IFN signaling pathway. We know that following B virus entry, virus replicates in dermal and epidermal layers of skin or mucosa. It has been shown by other laboratories, that
limiting the amount of virus production at the entry site reduces the amount of virus that subsequently
enters sensory nerve endings in the skin, thereby reducing the amount of virus that reaches the dorsal
root or cranial ganglia sub-serving the area of entry. My studies were undertaken to identify whether
there were differences between the responses of human pDCs and human and macaque PBMCs that
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can migrate into the damaged tissues and whether/how these differences affected the amounts of virus
produced.
Although the data presented in this dissertation disproved the hypothesis, these data contribute
to the understanding of the pathogenesis of B virus in both natural and foreign host cells by showing
that the IFN pathway is not differentially modulated in these hosts. Future studies are essential to understand the mechanism by which B virus is resistant to IFN because knowledge of this mechanism will
direct the identification of therapeutic targets. We showed that immune cells produce IFN- in response
to B virus and that B virus does not block the activation of IFN-pathways, therefore additional studies
are needed to explore how this IFN influences the overall host response to B virus or if the B virus resistance to IFN is limited to cells isolated from primary sites of infection. IFN- activates other innate
and adaptive immune cells and may play a critical role in B virus pathogenesis in the nervous system as
well as at peripheral sites. The delay or blockade of the production of neutralizing antibodies during ultimately fatal zoonotic infections is clearly one role that is distinctly different in humans and macaques.
The impact of my findings must be studied further with respect to IFN-activation of CD4 T cells and the
resultant activation of B cells capable of producing these neutralizing antibodies. Additional studies are
needed for understanding the mechanism of restricted production of IFN- during co-cultures of both
human and macaque cells, since this may be a target for modulation of immune responses within the
foreign host. Activation of pDCs with viral DNAs, such as those likely released in infected cell lysates,
may serve to increase the levels of IFN-to activate key adaptive immune responses.
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Figure 29 Working model of the role of pDCs in B virus infection
As a summary of this dissertation, our data support the model that if pDCs could gain access to infected peripheral
skin via a bite or a scratch from an infected monkey, they would respond to B virus infected fibroblasts with the production of cytokines and chemokines. These cytokines would recruit and activate a number of immune cells, including
monocytes, T cells, NK cells and other dendritic cells. Previous data from our lab showed that mDCs did not produce
cytokines in response to B virus infected fibroblasts (**R. Abraham, M. Vasireddi et al., 2012, unpublished raw data),
nor were NK cells functional as shown by their lack of production of perforin and granzyme (* M. Vasireddi et al.,
2010, in preparation), indicating B virus specific modulation of immune responses. Furthermore, this dissertation has
shown, that despite the production of cytokines, specifically IFN-, B virus replication was not reduced in fibroblasts.
These cytokines likely influence the microenvironment of immune cells in the infected skin, which may affect the accessibility of B virus to peripheral neurons or the rate at which it can enter, which may be more critical for survival
against B virus infection than the levels of B virus replication at peripheral sites.
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APPENDIX

Figure 30 Donor response to CpG
To determine if different donors had a differential response to CpG, we isolated pDCs from two different donors on
two different days. We also pooled the pDCs to determine if heterologous populations of pDCs would affect IFNproduction in pooled pDCs. pDCs were isolated from PBMCs and cultured with CpG at 10ug/ml for 24h. Supernatants were collected and analyzed for IFN- production by ELISA. The concentrations of IFN- differed between donors and differed by day in one donor. As expected, pooling of pDCs did not affect IFN-, but instead was an average
of the combined donor pDC IFN- production.

Figure 31 Verification of fibroblast isolation and purity from macaque whole skin biopsies
Fibroblasts were seeded into 8 well chamber slides and grown for 2 days. Cells were fixed with methanol, blocked
with 10%NGS and labled with anti-vimentin (green; left), -fibronectin (green; center) and –cytokeratin (red; right).
Nuclear stain was Hoescht (blue). RMFs were positive for vimentin and fibronectin, confirming fibroblast lineage but
negative for cytokeratin, indicating a lack of keratinocyte contamination.
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Figure 32 B virus kinetics in macaque and human fibroblasts
Fibroblasts were infected with B virus at an MOI of 10 in 24 well plates. Cell lysates were collected by scraping at 0, 1,
4, and 24hpi and stored at -80C. Samples were titrated by standard plaque assay. Red line=supernatants only, black
lines=supernatants and cells. Error bars represent SEM.
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Table 4 Raw data for B virus exposed pDCs of cytokine and chemokine production
Raw data for Luminex data presented in Figures 14 and X.15U=untreated, M=mock treated; B=B virus; H=HSV-1; 1, 2,
3 represent repeat wells. Black: below detection; blue: detectable range; red: above detection
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Table 5 Raw data for pDC cytokine and chemokine production in co-cultures
Raw data for Luminex data presented in Figures 16 and 17. U=untreated, M=mock treated; B=B virus; H=HSV-1; 1, 2, 3
represent repeat wells. Black: below detection; blue: detectable range; red: above detection

